Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs by Mccubrey, James A. et al.
www.aging‐us.com  1477  AGING 
  





James A. McCubrey1, Kvin  Lertpiriyapong2,  Linda  S.  Steelman1,  Steve  L. Abrams1,  Li V. Yang3, 







2Department  of  Comparative Medicine,  Brody  School  of Medicine  at  East  Carolina  University,  Greenville,  NC 
27858, USA 
3Department  of  Internal Medicine,  Hematology/Oncology  Section,  Brody  School  of Medicine  at  East  Carolina 
University, Greenville, NC 27858, USA  






























and SIRT1 molecules. CUR is isolated from the root of turmeric (Curcuma longa).  CUR  is  currently  used  in  the  
 










Hippocrates is reported to have stated, “Let food be thy 
medicine and medicine be thy food”. Numerous natural 
products/nutraceuticals derived from food, plants and 
other organisms have been evaluated for their effects on 
various medical conditions including: inflammation, 
bacterial and viral infections, obesity, diabetes, mental 
disorders, cardiovascular problems and more recently 
cancer.  
 
RES is being examined in at least 110 clinical trials on: 
age-related macular degeneration, aging, Alzheimer's 
disease (AD), cancer including, (colon, follicular 
lymphoma, liver cancer, multiple myeloma (MM) and 
neuroendocrine tumors), cardiovascular problems 
including, (diastolic heart failure, hypertensive heart 
disease, cerebral blood flow, heart failure, heart failure 
with preserved ejection fraction), chronic renal 
insufficiency, cellulite, cognitive disorders, dyslipidemia, 
diabetes, diabetic nephropathy, endometriosis, eye 
diseases, Friedreich Ataxia, Huntington disease, memory, 
metabolic disorders, mood disorders, polycystic ovary 
syndrome (PCOS), seasonal allergic rhinitis, 
nonalcoholic fatty liver disease, peripheral arterial 
disease, obesity, schizophrenia, sedentary lifestyle, sports 
concussion, and other disorders.  
 
CUR is being evaluated in at least 129 clinical trials for 
various conditions including: acute kidney injury, 
Alzheimer's disease, atopic asthma, cancer (breast, head 
and neck cancer, osteosarcoma, chronic lymphocytic 
leukemia, glioblastoma, cutaneous T-cell lymphoma, 
colo-rectal and rectal cancer (CRC),  non-small cell 
lung cancer, prostate, pancreatic neoplasms, multiple 
myeloma, myelodysplastic syndrome, cervical 
intraepithelial neoplasia),  schizophrenia, cardiovascular 
abnormalities, chemotherapy induced oral mucositis, 
Crohn's disease, chronic kidney disease, chronic 
obstructive pulmonary disease, chronic periodontitis, 
cystic fibrosis, diabetes (glucose tolerance and insulin 
resistance), end stage renal failure, erectile dysfunction, 
Helicobacter Pylori infection, hyperprolactinoma, 
inflammation in cancer patients, irritable bowel 
syndrome, knee osteoarthritis, lichen planus, major 
depression, metabolic syndrome, migraine, multiple 
sclerosis, optic atrophy, oral submucous fibrosis, 








arthritis, ulcerative colitis, vascular stiffness and other 
health problems.  
 
BBR is being examined in at least 35 clinical trials for 
treatment of: cardiovascular diseases, colorectal 
adenoma reoccurrence, diabetes, defective endothelial 
function, glucose metabolism/metabolic syndrome, 
Helicobacter pylori infection, hyperglycemia/glycemic 
control, hyper-lipemia, insulin sensitivity and insulin 
secretion, inflammation, non-alcoholic fatty liver 
disease, platelet aggregation, polycystic ovary 
syndrome and schizo-phrenia. Clearly these 
nutraceuticals, as well as many others, are being 
evaluated in the treatment of many health problems.   
 
Nutraceuticals effect on miR expression 
 
Nutraceuticals (natural products) have been proposed to 
exert their effects on CSCs by interacting with the 
expression of miRs. miRs such as: miR-21, miR-22, 
miR-34, miR-101, miR-146a miR-200 and let-7 have 
been associated with the CSC phenotype. miRs may be 
involved in drug resistance, invasion, metastasis and 
angiogenesis, key events in the biological charac-
teristics of CSCs [1,2].  
  
Natural products such as CUR, 3,3'-diindolylmethane, (-
)-epigallocatechin-3-gallate, indole-3-carbinol, isofla-
vone, RES and others may alter the expression of miRs. 
These changes may result in suppression of cell growth 
and induction of apoptosis. The natural products may 
also alter epithelial to mesenchymal transition (EMT) 
and the sensitivity to chemotherapy [3].   
 
Resveratrol-an anti-aging, anti-cancer nutraceutical 
 
RES has been evaluated in over 110 clinical trials, 
frequently consisting of diabetes and metabolic 
syndrome patients and certain types of cancer patients. 
In 2012, the global market for RES was estimated at 
$50 million (http://www.nutraingredients.com/Markets-
and-Trends/US-dominates-global - resveratrol - market). 
Many different effects on cellular physiology have been 
attributed/proposed for RES. It has been reported that 
RES affects NF-kappaB activity and inhibits cyto-
chrome P450 isoenzyme (CYP A1) drug metabolism 
and cyclooxygenase activity. Moreover, RES may 
influence TP53,  FAS/FAS-ligand  (FAS-L = CD95,  tu- 





www.aging‐us.com  1479  AGING 
mor necrosis factor receptor superfamily member 6 
[TNFRSF6]) induced apoptosis and mammalian target 
of rapamycin/mechanistic target of rapamycin (mTOR) 
activity and other biochemical pathways related to 
metabolism, oxidation of fatty acids, mitochondrial 
biogenesis and respiration and gluconeogenesis. RES 
may also induce apoptosis of activated T cells and 
suppress tumor necrosis factor-alpha (TNF-alpha), 
interleukin 17 (IL-17) and additional pro-inflammatory 
cytokines. Hence, it has been proposed that RES may be 
useful in auto-immune diseases. Importantly, RES may 
inhibit also the expression of hypoxia-inducible factor-
1alpha (HIF-1alpha) and vascular endothelial growth 
factor (VEGF) and thus may have anti-cancer 
properties. RES may also affect brain-derived neuro-
tropic factor expression which is important in obesity, 
diabetes, metabolic syndrome, depression, schizo-
phrenia, bipolar disorder, and autism. Thus, RES may 
be an important natural product which could be used to 
treat many medical disorders [4].  
 
RES is also present in Polygonum cuspidatum, which is 
also called bamboo in certain parts of the world and is 
considered an invasive weed. Thus, it could be 
inexpensive to produce large quantities of RES [5].  
 
There are other compounds that are structurally related 
to RES that inhibit CSCs. Bedaquiline is an anti-
microbiological agent that is used to treat multi-drug 
resistant tuberculosis. Recently it has been shown that 
bedaquiline inhibits the growth of mammary CSCs. 
Bedaquiline and RES inhibit the mitochondrial ATP-
synthase. Both bedaquiline and RES also have anti-
aging properties [6].  
  
RES has been shown to inhibit pancreatic beta cell 
dysfunction, arterial stiffening and metabolic decline 
that can occur after administration of a high-fat/high-
sugar (HFS) diet to nonhuman primates. In additional 
studies with this model, the effects on neuroprotection 
in the cortical brain tissue of these animals were 
investigated. These studies indicated that the non-
human primates which had been fed RES and the HFS 
diet had neuroprotection against cerebral vascular 
dysfunction. Decreased mitochondrial aldehyde de-
hydrogenase 2 levels, dysregulation in endothelial nitric 
oxide synthase, and reduced capillary density were 
observed in the non-human primates fed RES and HFS 
diet in comparison to monkeys fed only the HFS diet 
[7].  
 
Effects of resveratrol on sirtuins in cancer and aging 
 
RES induces sirtuins, a class of proteins involved in 
regulation of gene expression. Most sirtuins are histone 
deacetylates and in some cases, they are ADP-ribosyl 
transferases. The induction of sirtuins by RES may be 
responsible in part for the beneficial effects of the 
Mediterranean diet which is rich in RES [8].  
 
The inherent defense mechanisms in plants results in the 
production of the phytoalexins RES and pterostilbene. 
These compounds can affect gene methylation, 
however, the concentrations required to elicit these 
changes are higher than normally obtained by casual 
consumption of food and beverage products containing 
these compounds. The effects of these compounds have 
been examined on the hepatocellular carcinoma 
HCC1806 cells and the triple negative breast cancer 
(TNBC) MDA-MB-157 cell line and as a control the 
non-malignant breast epithelial MCF-10A cells. 
Combination of RES and pterostilbene at 
physiologically relevant concentrations resulted in a 
synergistic inhibition of cell proliferation. The 
expression of the SIRT1, gamma-H2A histone family-
member X (gamma-H2AX) and telomerase was 
detected at decreased levels in response to the combined 
treatment in HCC1806 and MDA-MB-157 cells but not 
in breast epithelial MCF-10A cells. Knockdown of 
SIRT1 mimicked the effects of resveratrol and 
pterostilbene on inhibition of SIRT1 in terms of the 
effects on telomerase and gamma-H2AX expression in 
HCC1806 breast cancer cells. The effects of these 
compounds on the ability of SIRT1 to recruit the DNA 
methyltransferases (DNMTs) were determined. These 
compounds resulted in down-regulation of the DNMT 
enzymes in the breast cancer cells but not in the MCF-
10A cells, thus RES appeared to target SIRT1 
specifically in breast cancer but not in normal cells [9].  
 
RES is also considered to be a SIRT1-activating 
compound (STACs). STACs may have potential in 
cancer treatment. However, the effects of RES remain 
controversial as it has been reported to increase as well 
as decrease the effects of chemotherapy. The effects of 
RES and the synthetic STAC SRT1720 on etoposide 
and vincristine-induced cell death of Ewing’s sarcoma 
cells were examined. The effects of STACs can depend 
on the TP53 gene status. In this study, the effects of 
STACs were examined in cells with different TP53 
genotypes, Ewing’s sarcoma cells with WT (WE-68), 
mutant TP53 (SK-ES-1) and TP53 null (SK-N-MC) 
gene configurations. Interestingly, when used as a 
single agent, the effects of the STACs were independent 
of TP53 gene status. However, when either SRT1720 or 
RES were added in combination with a chemo-
therapeutic drug, SRT1720 enhanced the effects of 
chemotherapeutic drugs on cell death while RES 
suppressed it [10].  
 
The Klotho gene is a tumor suppressor gene that may be 
important in age-associated diseases. It is activated by 
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RES in kidney cells. RES activates the activating 
transcription factor 3 (ATF-3)/c-Jun complex that 
results in Klotho expression. Dominant negative (DN) 
ATF-3 or c-Jun complexes suppressed the induction of 
Klotho in response to RES treatment [11].   
 
In the Invecchiare in Chianti (InChianti) study, RES 
levels (metabolites in 24-hour urine samples) were not 
associated with improvement in the longevity of the 
patient populations (783 men and women, 65 years or 
older) or inflammation, cancer or cardiovascular 
disease. The authors in this study concluded that RES 
levels were not associated with the levels of serum C-
reactive protein (CRP), interleukin-6 (IL-6), IL-1beta, 
TNF-alpha, cardiovascular disease, or cancer [12]. 
Thus, the roles of RES in anti-aging remain 
controversial.  
 
Effects of resveratrol on 5' adenosine mono-
phosphate-activated protein kinase (AMPK) 
 
RES may target nutrient sensing pathways which are 
implicated in aging and cancer. These pathways 
include, among others, insulin/insulin like growth 
factor-1 (IGF-1), mTORC, AMPK and sirtuins. When 
these pathways are active, they affect the conversion of 
normal cells into senescent cells and can result in 
abnormal aging, AD and growth (cancer) [13,14].  
  
Caloric restriction (CR) will function as a 
neuroprotector in Apolipoprotein E (ApoE)-deficient 
mice. This has recently been shown to be due to the 
upregulation of fibroblast growth factor 21 (FGF21) 
expression which phosphorylates AMPK that leads to 
decreased mTOR signaling which is important in AD 
[15]. AMPK has also been shown to be important in the 
life span of Caenorhabditis elgans. Induction of AMPK 
was determined to increase life span [16].  
  
The Sirtuin Sirt4 has been shown to regulate ATP 
homeostasis. Part of the effects of Sirt4 are due to a 
feedback loop involving AMPK [17].  
 
RES has been shown to regulate TP53 expression. TP53 
can regulate glucose metabolism. Treatment of serum-
deprived or RES-treated cells resulted in increased 
levels of the tumor suppressor TP53 protein. RES was 
shown to increase the TP53 promoter activity in HeLa 
S3 cells. This has been suggested to be in part 
responsible for the anti-aging effects that are elicited by 
RES [18].  
 
Resveratrol and senescence 
 
The induction of premature senescence after DNA 
damage in human primary dermal fibroblasts (BJ) has 
been associated with down-regulation of SIRT1 and 
SIRT2. RES was shown to decrease BJ proliferation 
and induce premature senescence. The phosphorylation 
of gamma-H2AX, and increased levels of TP53, p21Cip-1 
and p16INK4A were detected after RES treatment of BJ 
cells. In contrast, decreased levels of SIRT1 and SIRT2 
were observed after treatment of BJ cells with 
concentrations of RES which induced premature 
cellular senescence. Silencing SIRT1 or SIRT2 or 
treatment with sirtinol induced premature cellular 
senescence. Doxorubicin also suppressed SIRT1 and 
SIRT2 levels and induced premature senescence [19].  
 
Decreased levels of miR-15b were associated with 
increased expression of SIRT4 in cellular senescence 
and in photoaged skin. SIRT4 is linked with regulation 
of life span, metabolism and mitochondrial dysfunction. 
Senescence triggered by UVB or gamma irradiation of 
human dermal fibroblasts resulted in increased SIRT4 
expression. In contrast, decreased levels of miR-15b 
were detected. miR-15b can target the SIRT4 gene. 
These studies point to the importance of miR-15b in 
regulation of SIRT4 which is involved in cellular 
senescence, mitochondrial dysfunction and photoaging 
of human skin [20].  
 
Resveratrol and suppression of drug-induced 
cardiotoxicity 
 
RES has been shown to suppress doxorubicin-induced 
cardiotoxicity. The effect of RES on doxorubicin-
induced endoplasmic reticulum (ER) stress and 
cardiomyocyte apoptosis in H9c2 rat heart tissue cells 
was examined by determining the extent of activation of 
the SIRT1 pathway.  Treatment of H9c2 cells with 
doxorubicin was associated with increased expression 
of glucose‑regulated protein 78 (GRP78) and C/EBP 
homologous protein (CHOP). RES could maintain 
viability of the cells and decrease the expression of the 
ER stress proteins in the presence of doxorubicin. 
Combined treatment of RES and doxorubicin resulted in 
a significant increase in SIRT1 expression, whereas 
single treatment with either RES or doxorubicin only 
led to a slight increase in SIRT1 expression. Nicotina-
mide, a SIRT1 inhibitor, prevented the effects of RES 
on SIRT1 expression in doxorubicin-treated cells and 
suppressed the effects on GRP78 and CHOP. These 
results indicate that RES has protective effects on H9c2 
cells on doxorubicin-induced ER stress through 
activation of the SIRT1 pathway which may be 
important in the survival of cardiac and other cell types 
[21].  
 
In addition, RES has been shown to protect against 
doxorubicin-induced cardiotoxicity via restoration of 
SIRT1 and suppression of catabolic/apoptotic pathways 
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controlled by ubiquitin specific peptidase 7 (USP7), a 
TP53-deubiquitinating protein. 2-month-old (young) 
and 8-month-old (old) senescence-accelerated mice 
prone 8 (SAMP8) were treated with doxorubicin, and 
doxorubicin and RES, in the presence or absence of 
SIRT1 inhibitors, sirtinol or EX527. RES suppressed 
the induction of cardiotoxicity induced by doxorubicin. 
In these mice, the SIRT1 inhibitors prevented these 
effects of RES on doxorubicin-induced damage [22]. 
  
Resveratrol and exercise 
 
Exercise can prevent some of the frailty which results 
from aging. The effects of RES supplementation to aged 
and young mice (C57BL/6J, 16 month-old and 10 
week-old, respectively) that were involved in an 
exercise regime were analyzed. The performance of the 
mice was evaluated using forelimb grip strength and 
exhaustive swimming exercise. The plasma levels of 
lactate, ammonia, glucose, and creatine kinase were 
evaluated after exercise. The addition of RES improved 
the performance of the old but not young mice. The 
combination of RES and exercise training together was 
necessary to achieve enhanced performance and it may 
limit the extent of deterioration that normally occurs 
with aging [23]. 
  
The heart function in old rats has been shown to 
improve upon exercise or treatment with RES. While 
the RES and exercise treatments each resulted in 
activation of the PI3K/PTEN/Akt pathway, only the 
RES-treated rats displayed elevated SIRT1. The 
combination of RES and exercise treatment was 
determined to enhance FOXO3 phosphorylation by 
activation of PI3K/PTEN/Akt and SIRT1 pathways in 
the swimming exercise model of aged rats. Increased 
levels of SIRT1 and PI3K/PTEN/Akt were detected in 
the groups of rats that underwent treatment with RES 
and exercise treatment as well as increased levels of 
phosphorylated FOXO3 which results in its inactivation 
[24].  
  
The effects of exercise training and RES on vascular 
health in aging is influenced by various factors. 
Impaired vascular function is often due to endothelial 
dysfunction. This may be mediated by an altered redox 
balance which may result from increased reactive 
oxygen species (ROS) and decreased antioxidant 
ability. These changes result in decreased amounts of 
nitric oxide (NO). Physical inactivity and aging have 
negative effects on the vascular system. The NO 
bioavailability, redox balance and plasma lipids are 
improved by exercise. Some of these effects are 
mediated by SIRT1, AMPK and the estrogen receptor 
(ER). It turns out that RES can also activate these 
pathways, however, in some cases, RES can 
counteractive the positive effects of regular exercise 
[25].  
  
Resveratrol enriched rice (DJ526) has been generated 
by genetic modifications that enables the rice plant to 
synthesize RES. This rice has been examined for its 
effects on physical strength and motor coordination. 
This DJ526 rice improved changes associated with 
aging [26].  
 
Resveratrol and diabetes 
 
RES induces SIRT1, that may modulate Foxo1 
signaling which is important in insulin signaling. Foxo1 
inhibits glucose uptake and utilization in skeletal 
muscles. SIRT1 may deacetylase and suppress Foxo-1 
which has effects on the transactivation of pyruvate 
dehydrogenase lipoamide kinase 4 (PDK4). PDK4 is a 
negative regulator of the glycolytic enzyme pyruvate 
dehydrogenase (PDH). Thus, RES has effects on 
glycolysis in aging skeletal muscle and insulin 
sensitivity. RES may have effects on prevention of 
reduction of skeletal muscle and insulin sensitivity, two 
important components in aging and diabetes [27].  
 
Many of the beneficial effect of RES, CUR and BBR 
have been attributed to their anti-inflammatory 
properties. They have beneficial effects in pancreatic 
beta-cell function by suppressing phosphodiesterase 
activity which plays critical roles in glucose- and 
incretin-stimulated insulin secretion that is important in 
type 2 diabetes. The phosphodiesterases, which 
normally degrade cAMP, are important targets in type 2 
diabetes. Recently, it was determined that both RES and 
CUR inhibit phosphodiesterase activity. RES and CUR 
were observed to suppress the expression of mRNAs 
encoding many of the phosphodiesterase isoforms such 
as: PDE3B, PDE8A, and PDE10A. These phospho-
diesterase isoforms are important in the regulation of 
insulin secretion in the islets. These results suggest that 
RES and CUR could be important in the treatment of 
certain diabetics as they may enhance pancreatic beta-
cell function [28].   
 
Both RES and melatonin (MEL) will activate SIRT1 
expression. Endogenously produced melatonin 
decreases with aging and is responsible for some of the 
deleterious effects associated with aging. MEL and RES 
are both found in some foods and may have anti-aging 
effects. CR will also activate sirtuin expression [29].  
 
Resveratrol and memory loss 
 
RES has been shown to inhibit memory loss and mood 
dysfunction which can occur during aging. This occurs 
via increased hippocampal neurogenesis and micro-
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vasculature and inhibition of glial activation in small 
rats. RES supplementation resulted in improved 
learning in the rats. This has been associated with 
increased angiogenesis and decreased astrocytic 
hypertrophy and decreased microglial activation in the 
hippocampus. The beneficial effects of RES may be due 
to effects on the hippocampus plasticity and suppression 
of chronic low-level inflammation. This study suggests 
that addition of RES to the diets of adults could have 
promise in preventing some of the deleterious effects 
that aging has on memory and other related functions 
[30].  
 
Importantly, the effects of RES have been examined on 
human subjects. RES was shown to enhance memory 
performance and glucose metabolism in older heathy 
adults. 23 patients (50-75 years old) consumed RES, 
while 23 received placebo for 26 weeks. Patients treated 
with RES also exhibited decreased glycated hemoglobin 
(HbA1c) and body fat, and increases in leptin in 
comparison with control patients treated with placebo 
[31].  
 
Resveratrol and Alzheimer’s disease-enhancing 
cerebral circulating function 
 
RES may have neuroprotective roles in AD and may 
improve memory function in dementia. In studies with 
rats in a water maze model, RES inhibited the 
expression of inflammatory cytokines (TNF-alpha and 
IL-1beta) in the older rats. The studies point to potential 
benefits of RES in terms of memory decline which 
occurs during aging [32]. In a rat model of ibotenic acid 
induced AD, RES was shown to ameliorate memory 
deficiency associated symptoms, alleviating cholinergic 
pathways, and reduce oxidative stress [33]. In a mouse 
model with beta amyloid (Abeta1)-42-induced cognitive 
impairment, RES was shown to inhibit phosphodies-
terase-4 related signaling which is important in beta 
amyloid-induced memory impairment [34]. miR-603 
has been associated with AD risk and pathogenesis. 
miR-603 binds the 3’untranslated region of low density 
lipoprotein-related protein-associated protein 1 
(LRPAP1) mRNA and downregulates the mRNA and 
protein [35]. LRPAP1 acts as a chaperone to aid in the 
trafficking of the LDL receptor family members, LRP1 
and LRP2. LRPAP1 and LRP1 have opposite effects. 
miR-603 decreases LRPAP1 levels while increasing 
LRP1 levels. miR-603 and the associated rs11014002 
single nucleotide polymorphism (SNP) may serve as a 
protective factor against AD. The SNP promotes the 
biogenesis of mature miR-603 and has a protective 
effect with regards to AD risk. The expression of the 
LRPAP gene is down regulated by miR0603 binding the 
3’UTR. In contrast, miR-603 increases LRP1 
expression. LRP1 and LRPAP1 are involved in Abeta 
protein clearance and AD pathogenesis. 
 
Resveratrol and aging in the eyes 
 
The roles of RES and SIRT1 in controlling the 
resistance to oxidative stress in lens epithelial cells 
(LECs) have been examined.  RES is an activator of 
SIRT1.  Cells were treated with RES and an inhibitor of 
SIRT1, nicotinamide, and incubated with H2O2 which 
induces oxidative stress. The effects of this treatment on 
SIRT1, TP53 and acetylated TP53 were examined. 
Upon H2O2 treatment, SIRT1 was increased and 
increased further upon RES treatment. RES prevented 
the morphological changes and apoptosis induced by 
H2O2 treatment and promoted proliferation and a 
decrease in acetylated TP53. Nicotinamide treatment, 
on the other hand, enhanced apoptosis under oxidative 
stress conditions, decreased proliferation and resulted in 
increased acetylated TP53. The TP53 inhibitor pifithrin-
alpha (PFT-alpha) prevented the effects of nicotinamide 
[36].   
 
The ability of SIRT1 to serve as a regulator of aging in 
the retina has been examined after 1 month and 19 
months after oral administration of RES to rats. The 
expression of SIRT1, brain derived neurotropic factor 
(BDNF) and tropomyosin receptor kinase B (TRKB) 
was examined in these studies. SIRT1 was determined 
to decrease in aged retinas in comparison to young 
retinas. The expression of BDNF, TRKB and SIRT1 
and b-wave amplitude was increased in the retinas upon 
RES treatment. More apoptosis was detected in the aged 
rat retinas which did not receive RES than in the retinas 
of the rats which did receive RES. These studies suggest 
that RES treatment increased SIRT1 levels may prevent 
some of the deleterious effects associated with retina 
aging [37].  The effects of RES on macular degene-
ration were examined. RES had effects on TGF-beta 
and hypoxia-induced VEGF secretion by human retinal 
pigment epithelial cells (HRPE) that were derived from 
elderly patient’s eyes. Treatment with cytokines such 
as: interferon-gamma (IFN-gamma), TNF-alpha and IL-
1beta resulted in increased expression of vascular 
endothelial growth factor-A (VEGF-A) and VEGF-C in 
the eye cultures. RES suppressed the secretion of the 
VEGF-A and VEGF-C in the eye cultures. RES was 
also demonstrated to suppress the mobility of the eye 
cells in scratch wound closure assays. Overexpression 
of VEGF is often associated with macular degeneration 
and one the treatments is by ocular injection of a 
monoclonal antibody such as bevacizumab which is 
directed to VEGF.  RES may be beneficial in the 
treatment of macular degeneration and diabetic 
retinopathy [38].  
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miR-320a has been shown to target the VEGF signaling 
pathway. Elevated miR-320a expression was 
determined to reduce cardiac microvessel density. This 
resulted in decreased cardiac function in mice treated 
with doxorubicin. VEGF-A is a target of miR-320a. 
These results indicate that miR-320a and VEGF-A play 
key roles in cardiotoxicity induced by doxorubicin. 
Targeting miR-320a may alienate some of the 
cardiotoxicity associated with doxorubicin treatment by 
suppressing miR-320c [39].  
 
Resveratrol and hearing loss 
 
The expression of TP53/miR-34a/SIRT-1 axis was 
examined during aging in cochlear hair cells which are 
involved in hearing and deafness. Increased levels of 








































in cochlear hair cells from aged C57BL/6 mice while 
the levels of SIRT-1 decreased. Overexpression of miR-
34a was determined to inhibit SIRT1 expression in the 
inner ear HEI-OC1 cell line. This resulted in increased 
TP53 acetylation and apoptosis. In contrast, suppression 
of miR-34a increased SIRT1 expression and decreased 
TP53 acetylation and apoptosis. RES was shown to 
rescue the detrimental effects of miR-34a over-
expression on HEI-OC1 cells and had positive effects 
with regards to protection from hearing loss and hair 
cell loss in C57BL6/J mice [40].  
  
Potential of resveratrol in cancer and CSCs 
 
The abilities of RES to inhibit various types of cancer 
have been examined. RES has been shown to stimulate 









































RES  are  indicated.  This  diagram  focusses  on  signaling  pathways  predominately  involved  in  aging  and  cancer.  Red  arrows  indicate
induction of an event; black closed arrows indicate suppression of an event. 
www.aging‐us.com  1484  AGING 
and autophagy. In some cases, RES has been shown to 
synergize with chemotherapeutic drugs and inhibit 
proliferation. We will briefly summarize some of the 
different types of cancer that RES has been examined 
on. We will focus primarily on RES and CSCs. An 
overview of the pleiotropic effects of RES on cancer 
pathways is presented in Figure 1. 
 
Effects of resveratrol on brain cancer 
 
The effects of RES on the induction of autophagy and 
apoptosis were examined in glioblastoma (GBM) CSCs. 
RES induced autophagosome formation in three GBM 
cell lines. The expression of proteins associated with 
autophagy such as: autophagy protein 5 (Atg5), beclin-1 
and Microtubule-associated proteins 1A/1B light chain 
3B (LC3-II) were increased after RES treatment. 
Suppression of the autophagy induced by RES resulted 
in apoptosis. Suppression of both autophagy and 
apoptosis was required to block the toxicity of RES. 
RES suppressed the sphere-forming capacity of the 
GMB cells and the percentage of CD133 and octamer-
binding transcription factor-4 (OCT4) positive cells 
[41].  
 
Increased levels of signal transducer and activator of 
transcription 3 (STAT3) have been detected in CD133+, 
GMB CSCs. Suppression of STAT3 by either 
pharmacological or genetic approaches inhibited the 
CSC properties of GMB CD133+ cells. RES was 
determined to inhibit STAT3, induce apoptosis, 
suppress the stemness gene signature and induced 
differentiation. RES or sh-STAT3 treatment was 
determined to suppress GBM CSC survival in mice and 
their combined treatment synergistically increased 
radiosensitivity [42].  
 
The effects of RES on human U87MG cells and 
primary human glioblastoma cultures were examined. 
RES suppressed the invasive growth and stimulated 
differentiation. RES decreased NESTIN and stimulated 
glial acidic fibrillary protein and betaIII-tubulin and 
senescence [43].  
 
RES inhibited the self-renewal and tumor-initiating 
capacity of patient-derived glioblastoma stem cells 
(GSC). RES was determined to suppress the expression 
of NANOG through proteasomal degradation which 
could be inhibited by the proteasome inhibitor MG132. 
TP53 activation is important in the suppression of 
NANOG after RES treatment. RES treatment activated 
TP53 and p21Cip1. Suppression of NANOG inhibited 
self-renewal and tumor-forming capacity of the GSCs. 
These studies indicated that RES could induce GSC 
differentiation and NANOG was important in stemness 
[44].  
The effects of RES have been compared on GSCs and 
normal neural stem cells (NSCs). RES was determined 
to block GSC proliferation, while it did not appear to 
have any effects on NSCs. SIRT1 and SIRT3 were 
expressed in both GSCs and NSCs, however, SIRT2 
was only expressed in GSCs.  Inhibition of SIRT2 
suppressed the anti-proliferative effects of RES [45].  
 
The effects of combining RES with radiation have been 
examined in the radioresistant GBM SU-2 cell line. 
RES was demonstrated to inhibit proliferation, enhance 
radiosensitivity, suppress neural stem cell markers and 
induce differentiation in SU-2 cells. The combination of 
RES and radiation resulted in increased autophagy, 
apoptosis in in vitro and in vivo models. In addition, 
RES treatment suppressed repair of radiation-induced 
DNA damage [46].  
 
Effects of resveratrol on breast cancer 
 
RES inhibited the proliferation of CSCs isolated from 
MCF-7 and SUM159 breast cancer cells. RES also 
reduced the presence of mammospheres in these two 
cell lines and inhibited tumor formation of the 
mammospheres in NOD/SCID mice. RES also induced 
autophagy in the breast mammospheres as determined 
by analysis of GFP-LC3-II puncta formation assay and 
the levels of LC3-II, Beclin1 and Atg 7 proteins. RES 
suppressed WNT/beta-catenin pathway expression [47].  
 
The abilities of RES and the chemically-related 
pterostilbene to combine and restore the ERalpha 
expression in ERalpha-negative breast cancer have been 
examined. After combined treatment with RES and 
pterostilbene, increased levels of active acetyl-H3, 
acetyl-H3lysine9 (H3K9) and acetyl-H4 binding to the 
ERalpha promoter analysis were observed by chromatin 
immunoprecipitation analysis (ChIP). The combined 
treatment also resulted in changes in HDAC and histone 
acetyl transferase activity (HAT) as reduction in DNMT 
enzyme activity and 5-methylcytosine levels were 
observed in the normally ER- MDA-MB-157 breast 
cancer cells. The combined treatment also rendered the 
cells sensitive to the ER antagonist tamoxifen. This 
combination approach may be a safer alternative to 
restore ER expression and sensitivity to anti-ER based 
therapeutics in certain breast cancer patients [48]. 
 
The effects of the RES analog 4,4'-dihydroxy-trans-
stilbene (DHS) were examined on normal mouse and 
human fibroblasts and human breast cancer cells. DHS 
was determined to inhibit the growth of human 
fibroblast cells more than normal RES. DHS was 
determined to suppress chemically-induced (3-
methylcholanthrene plus 12-O-tetradecanoylphorbol-
13-acetate) transformation of BALB/c-3T3 and 
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invasion of MCF-7 breast cancer cells. Interestingly, 
DHS was determined to inhibit both anchorage-
dependent and anchorage-independent growth of 
MCF-7 growth more efficiently than RES. DHS 
resulted in pRb inhibition and increased expression of 
TP53 and p21Cip-1.  DHS was determined to reduce 
matrix metalloproteinase-2 (MMP2) and MMP9 
expression, decreased adhesion to the extracellular 
matrix, migration and invasion [49].  
  
Dihydrotestosterone (DHT) can stimulate the growth of 
breast cancer cells. DHT can interact with both ERalpha 
and integrin alphavbeta3. RES can induce TP53-
dependent apoptosis via integrin alphavbeta3. ERK1/2 
can transduce, in part, the signals mediated by RES and 
DHT, while DHT promotes proliferation, RES induces 
apoptosis. The effects of RES and DHT were compared 
on MCF-7 (ERalpha+) and MDA-MB-231 (ERalpha-) 
breast cancer cells. DHT was determined to inhibit 
phosphorylation of TP53 at S15. DHT also inhibited the 
nuclear TP53/COX-2 complex and TP53 transcriptional 
program. Thus, the receptor sites necessary for the 
effects of DHT and RES are discrete. While they both 
result in activation of ERK1/2 they have different 
effects. These studies also indicate the importance of 
the presence and absence of DHT in studies evaluating 
the effects of RES [50].   
 
The effects of RES were examined in paclitaxel-resistant 
MDA-MB-231 cells. RES was determined to inhibit 
proliferation and stimulate apoptosis and cellular 
senescence in both paclitaxel-resistant and paclitaxel-
sensitive MDA-MB-231 cells indicating that the effects 
of RES were independent of the paclitaxel-sensitivity 
status of the MDA-MB-231 cells. The resistant cells 
expressed increased levels of multidrug resistance-1 
(MDR1) and cytochrome P4502C8 (CYP2C8) genes 
[51].  
 
Effects of resveratrol on colorectal cancer (CRC) 
 
The diet is very important in the development of cancer, 
especially CRC. CRC CSCs are resistant to 
conventional chemotherapeutic drugs. The Western diet 
is becoming more and more associated with obesity 
which results in elevated levels of insulin and IGF-1. 
This may contribute  to  activation  of  the  PI3K/PTEN/ 
Akt/mTORC1 and WNT/beta-catenin path-ways which 
contributes to CRC CSCs as well as premature aging. 
These CRC CSCs are often resistant to small molecule 
inhibitors which target these signaling pathways. A 
current focus of nutrition research is the effects of 
dietary bioactive compounds such as: CUR, grape seed 
extract, lycopene (present in tomatoes and other red 
vegetables), RES and others [52].  
SIRT1 is an important subcellular target for RES. 
Depending on the cell system and conditions, RES can 
act as a tumor promoter or a tumor suppressor. The 
effects of RES on the SIRT1 were examined in CRC 
cells. RES suppressed proliferation in two CRC cell 
lines, this was accompanied with a decrease in Ki-67 
expression which was dependent upon SIRT1 activity. 
RES downregulated nuclear localization and activity of 
NF-kappa-B which resulted in decreased expression of 
MMP9 and C-X-C chemokine receptor type 4 (CXCR4), 
two proteins associated with metastasis. SIRT1 was 
determined to interact with NF-kappaB. RES can effect 
SIRT1 expression which can regulate negatively NF-
kappaB activity [53].  
  
RES has been determined to suppress proliferation, 
migration, invasion and induce apoptosis in CRC cell 
lines, such as HT-29 (TP53+) and HCT-116 (TP53-) 
CRC cell lines. 
  
The expression of miR-34c is increased by RES in CRC 
and this expression was in part responsible for the 
effects of RES. RES also sensitized the CRC cells to 
oxaliplatin in a miR-34a-dependent fashion. In 
xenograft studies, treatment with either RES or oxalip-
latin suppressed tumor growth and their combined 
treatment was synergistic. In this xenograft system, 
RES increased miR-34 levels and also reduced the level 
of IL-6 which normally promotes CRC progression. The 
effects of RES were increased in the presence of 
functional TP53, indicating that RES and TP53 
synergized [54].  
 
The pharmacological properties of RES can be 
enhanced by nanoencapsulation. Normally the solubility 
and stability of RES is poor. The effects of nanoen-
capsulation of RES have been examined in CRC and 
other model systems and have shown enhanced delivery 
[55].  
  
A common problem with 5-flurouracil (5FU) treatment 
of CRC patients is chemo resistance. The effects of RES 
on 5FU-sensitive (HCT116, SW480) and their 
corresponding isogenic 5FU-chemoresistant derived 
CRC cell clones (HCT116R, SW480R) have been 
examined. Interestingly, RES blocked proliferation of 
all four cell lines and synergized with the effects of 
5FU. RES was determined to suppress many gene 
products associated with EMT such as decreased 
vimentin and SLUG expression but increased E-
cadherin expression. RES down-regulated NF-kappaB 
activation and nuclear translocation resulting in 
inhibition of NF-kappaB regulated gene expression 
which included MMP-9 and caspase-3. This occurred 
by inhibition of IkappaBalpha kinase which controls 
NF-kappaB activity [56].  
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The abilities of RES to suppress the cisplatin-resistance 
of CRC cells have been examined. The effects of 
addition of 15 micrograms/ml RES were determined on 
CRC cells treated with 5 and 20 micrograms/ml 
cisplatin. RES could induce anti-proliferative and pro-
apoptotic effects in both the drug-sensitive and 
cisplatin-resistant HCT-116 cells. The cellular uptake of 
cisplatin was improved in the presence of RES [57].  
 
The effects of RES also have been examined in 
combination with oxaliplatin in the HCT116 CRC cell 
line. The effects of RES and oxaliplatin were examined 
on the inhibitor of apoptosis protein survivin which is a 
key anti-apoptotic protein. While oxaliplatin treatment 
decreased the levels of survivin, the combined treatment 
of oxaliplatin and RES restored survivin, BCL-2 and 
caspase levels. In these studies, the apoptotic-inducing 
effects of oxaliplatin were decreased when RES was 
added to the HCT116 cell line. Thus, in the HCT116 
cell line, RES had an anti-chemosensitizing effect when 
added with oxaliplatin. These and other studies 
demonstrate the caution that needs to be applied to 
studies with using RES on CRC and other cancer types 
[58].  
 
The abilities of RES to enhance the anti-proliferative 
effects of etoposide in HepG2 liver cancer cells and 
CRC HCT-116 cells were determined. Both cell lines 
have functional TP53. RES inhibited proliferation in 
both cell lines. The combination of RES and etoposide 
resulted in greater anti-proliferative effects in HCT-116 
than just after etoposide treatment by itself whereas this 
effect was not observed in HepG2 cells. TP53 was 
detected at higher levels after RES and etoposide 
treatment. Pre-incubation of both cell lines with RES, 
increased the level of etoposide-induced TP53. Thus, 
RES appeared to promote the effects on TP53 [59].  
 
RES can induce AMPK which results in inhibition of 
the drug transporter MDR1 in oxaliplatin-resistant (L-
OHP) HCT116/L-OHP CRCs. This prevents NF-
kappaB activation and levels and suppresses cAMP-
responsive element transcriptional activity. AMPKalpha 
siRNA transfection could reverse the effects of RES on 
MDR1 expression and cAMP-responsive element-
binding protein (CREB) phosphorylation [60].  
  
RES induces chromatin condensation and TP53 and the 
cleavage of poly [ADP-ribose] polymerase 1 (PARP-1) 
in CRC cells. The TP53 gene status was determined to 
affect the sensitivity to RES as CRC cells with WT 
TP53 (HCT-116/p53 WT) were more sensitive to RES 
than cells with mutant TP53 (HCT-116/p53-/-). RES 
induced double strand DNA breaks by interfering with 
type II topoisomerase. This was ascertained by 
determining the extent of gamma-H2AX foci present 
after treatment with RES. The DNA damage was 
determined to be due to type II topoisomerase 
poisoning. Treatment of HCT-116 cells with RES was 
determined to result in activation of Ataxia 
Telangiectasia Mutated (ATM) kinase which in turn 
activated TP53 [61].  
  
RES suppresses EMT via the TGF-beta/SMAD pathway 
in CRC LoVo cells in vitro and in animal experiments 
in vivo. The TGF-beta/SMAD pathway regulated 
SNAIL/E-cadherin expression. RES inhibited CRC 
metastasis into the lung in colon cancer metastatic 
tumor model after tail vein injection as well the 
development of lung and liver tumors after orthotopic 
injections. In vitro studies showed that TGF-beta 
promoted EMT and invasion and reduced E-cadherin 
but elevated vimentin expression. RES inhibited cancer 
cell invasion and induced E-cadherin and repressed 
EMT, vimentin, the TGF-beta/SMAD pathway and 
SNAIL [62].   
  
The effects of RES and the DNA cross-linker 
mitomycin C have been examined in CRC primary CRC 
cells isolated from resected tumors. The combination of 
RES and mitomycin C suppressed proliferation better 
than either drug by itself. This treatment resulted in a 
significant up-regulation of p21Cip-1 expression [63].  
  
The effect of RES and 5-aminosalicylic acid 
(Mesalazine) on JAK/STAT activation have been 
examined in the HT-29 CRC line. Mesalazine is an anti-
inflammatory drug used to treat patients with bowel 
disorders, including inflammatory bowel disease. RES 
reduced nitric oxide (NO) and prostaglandin E2 (PGE2) 
production, inducible nitric oxide synthase (iNOS) and 
cyclooxygenase-2 (COX-2) expression and ROS 
production which were induced by treatment of HT-29 
cells with the inflammatory cytokines (IL-1alpha, TNF-
alpha, IFN-gamma). RES was determined to decrease 
activation of the JAK/STAT pathway but did not result 
in degradation of I-kappaB-alpha. RES also inhibited 
stress-activated protein kinase (SAPK)/c-Jun N-terminal 
kinase (JNK) pathway activation [64].  
  
In a different study, RES was shown to inhibit the 
proliferation of human HCT116 CRC cells in vitro as 
well as in tumor xenograft studies in vivo. RES was 
determined to upregulate phosphatase and tensin 
homolog (PTEN) expression and decrease the 
expression of activated Akt. In HCT116 cells, PTEN 
inhibits Akt signaling and proliferation. Moreover, 
decreased levels of beta-catenin were also detected after 
RES treatment [65].  
  
RES was shown to decrease WNT/beta-catenin pathway 
activity and the downstream targets c-Myc and MMP-7 
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in CRC cells.  RES also decreased the expression of 
long non-coding metastasis associated lung 
adenocarcinoma transcript 1 (RNA-MALAT1) in the 
LoVo and HCT116 CRC cells. This resulted in 
decreased nuclear localization of beta-catenin and 
suppressed WNT/beta-catenin signaling. These events 
were linked with suppression of CRC invasion and 
metastasis [66].   
 
Treatment of CRC cells with RES resulted in decreased 
expression of transcription factor 4 (TCF4), which is a 
critical effector molecule of the WNT/beta-catenin 
pathway. The half-life of the TCF4 protein was 
decreased after treatment with RES. In contrast, RES 
did not affect the transcription rate of the TCF4 gene. 
RES increased the S/T phosphorylation of TCF4. These 
phosphorylation events were determined to be due to 
ERK1/2 and p38MAPK [67].  
 
RES can induce anti-proliferative effects on CRC cells 
via the miR-34a/E2F3/Sirt1 pathway. The effects of 
RES, epigallocatechin-3-gallate (EGCG), and alpha-
mangostin (alpha-M) were examined on three CRC 
lines in the presence and absence of 5-FU. These natural 
products were determined to  suppress  the  PI3K/PTEN/ 
Akt/mTORC1 pathway. Alpha-M was determined to be 
the most potent PI3K/PTEN/Akt/mTORC1 pathway 
inhibitor and suppressed Raf/MEK/ERK pathway. 
Combined treatment of RES and 5-FU resulted in a 
synergistic inhibition of cell growth and induction of 
apoptosis and the Raf/MEK/ERK pathway was 
suppressed in DLD-1 CRC cells. RES increased the 
expression of miR-34 which resulted in the decreased 
expression of E2F3 and SIRT1 [68].  
 
Effects of resveratrol on head and neck cancer 
 
The effects of RES on the CSC properties of head and 
neck cancer-derived tumor-initiating cells (HNC-TICs) 
were examined. RES was determined to downregulate 
ALDH1 and CD44 in HNC-TICs in a dose-dependent 
fashion. RES also inhibited OCT4, NANOG and 
NESTIN expression in the sphere forming HNC cells. 
In mouse experiments, RES was shown to inhibit tumor 
growth, stemness and EMT markers. RES synergized 
with chemotherapy in suppression of the growth of 
HNC-TICs [69].  
 
Effects of resveratrol on leukemia 
 
RES suppressed phosphorylated liver kinase B1 
(pLKB1) and induced senescence and apoptosis in acute 
myeloid leukemia (AML) KG1a cells. This occurred via 
SIRT1 which is a regulator  of  LKB1 (aka  serine/threo- 
nine kinase 11 [STK11]) which resulted in senescence 
and apoptosis [70].  
RES has been determined to decrease IL-6-induced 
Sonic hedgehog homolog (SHH) signaling in AML. The 
plasma levels of IL-6 and IL-1beta were higher and 
lower respectively in AML patients than in normal 
donors. The expression of SHH was determined to be 
higher in bone marrow and peripheral blood 
mononuclear cells prepared from AML patients. IL-6 
was determined to increase SHH and GLI-1 expression 
in HL-60 cells. IL-6 also increased cell viability. RES 
decreased SHH expression, GLI-1 nuclear translocation 
and cell viability in IL6-treated HL-60 cells. RES was 
determined to synergize with the SHH inhibitor 
cyclopamine in inhibiting growth [71].  
 
Effects of resveratrol on lung cancer 
 
RES has been shown to inhibit the secretion of IL-6 and 
VEGF from A549 lung cancer cells when they were co-
cultured with adipose-derived mesenchymal stem cells 
[72].  
 
The ability of combined RES and metformin (MET) 
treatment to protect A549 lung cancer cells from 
ultraviolet C (UVC)-induced damage was determined. 
MET was determined to inhibit the UVC-mediated 
increase in TP53 expression and suppressed expression 
of gamma-H2AX and phosphorylated check kinase-2 
(P-Chk2). MET also induced DNA repair and cell cycle 
arrest and decreased levels of cyclin E/cyclin-dependent 
kinase 2(cdk2)/RB and cyclin B1/CDK1. Treatment 
with RES, by itself, was less effective in suppressing 
UVC-induced responses. Combined RES and MET 
treatment resulted in a synergistic response in terms of 
decreased TP53, gammaH2AX and P-Chk2 expression. 
Thus, the combination of RES and MET might suppress 
some of the aging effects elicited by UVC-induced 
DNA damage [73].  
 
RES has been shown to regulate the expression of 
lncRNAs in lung cancer. 21 lncRNAs were shown to 
have increased expression after RES treatment and 19 
lncRNAs were detected at lower levels in A549 lung 
cancer cells. The AK001796 lncRNA was determined to 
be overexpressed in lung cancer cell lines and tissues 
but it was detected at lower levels in RES-treated cells. 
The AK001796 lncRNA functioned as an oncogene. 
Suppression of AK001796 lncRNA inhibited cell 
growth and promoted cell cycle arrest [74].  
 
Effects of resveratrol on hepatocellular carcinoma  
 
The effects of RES on hexokinase 2 (HK2) were 
examined in HCC. HK2 can change the metabolic 
properties of cancer cells to promote growth in 
conditions of low oxygen concentrations. This can 
result in aerobic glycolysis. Aerobic glycolysis was 
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observed in four HCC lines as opposed to normal 
hepatic cells. Treatment with RES was observed to 
sensitize the HCC cell lines to apoptosis and these 
effects were reversed upon treatment with glycolytic 
inhibitors. RES treatment resulted in a decrease in HK2 
and increased mitochondrial-induced apoptosis. RES 
could enhance treatment with sorafenib resulting in 
growth inhibition and promoting apoptosis in HCC 
xenografts in mice [75].  
  
The effects of tanshinone IIA (Tan IIA) have been 
examined in combination with RES on the induction of 
cytotoxicity, cell-cycle arrest, apoptosis, and DNA 
fragmentation in HepG2 HCC cells. Tan IIA and RES 
were determined to synergize in inducing apoptosis. 
The levels of apoptosis induced with Tan IIA and RES 
were similar to the amounts induced by cisplatin [76].   
  
RES has been shown to induce apoptosis in HepG2 
cells by induction of caspase-3 and -9, TP53 and 
increasing the BAX/BCL2 ratio. The ability of matrine, 
a natural component extracted from the traditional 
Chinese medical herb Sophora flavescens Ait to 
synergize with RES was determined also. Matrine could 
synergize with RES in inhibiting cell growth and 
promoting apoptosis. This synergy in the induction of 
apoptosis was attributed to the induction of caspases -3 
and -9, downregulation of survivin, induction of ROS 
and alteration of the mitochondrial membrane potential 
[77]. The effects of RES on VEGF expression and 
proliferation of HCC cells were determined. RES 
inhibited VEGF expression in the HepG2 cells [78].  
  
RES was determined to sensitize HepG2 cells to TNF-
related apoptosis-inducing ligand (TRAIL)-induced 
apoptosis. RES induced an increase in phospho-AMPK 
levels and a decrease in survivin levels. RES was 
determined to increase TRAIL sensitivity by decreasing 
survivin expression [79]. 
  
The effect of RES on the induction of apoptosis in 
SMMC-7721 cells were determined. RES could activate 
caspases-3 and -9 and JNK whereas it downregulated 
activated ERK. RES also was effective in xenograft 
models with SMMC-7721 cells [80].  
  
RES has been shown to suppress the STAT3 signaling 
pathway in HepG2 cells. This resulted in the 
suppression of proliferation when the cells were 
cultured in medium containing high glucose. This was 
determined to be mediated in part by SIRT1 expression. 
When HepG2 cells were cultured in medium containing 
25 millimolar glucose, exposure of the cells to 100 
micromolar Res suppressed proliferation and STAT3 
signaling [81].  
Res has also an anti-metastatic effects in HCC through 
inhibition of phosphorylation of the JNK 1/2 pathway 
and SP-1 DNA binding activities, causing a down-
regulation of urinary-type plasminogen activator (u-PA) 
expression [82].  
 
RES prevented diethylnitrosamine (DEN)–induced liver 
tumorigenesis in rats by suppressing oxidative stress 
and inflammatory response mediated in part by hepatic 
nuclear factor E2–related factor 2 (Nrf2) [83]. RES in 
combination with CUR has synergistic antiproliferative 
effects in HCC Hepa1-6 cells [84].  
 
Effects of resveratrol on nasopharyngeal cancer 
 
The effects of RES on nasopharyngeal carcinoma 
(NPC) CSCs were examined. Interestingly the NPC 
CSCs were determined to have undergone a metabolic 
shift as they relied on glycolysis for energy. RES was 
determined to shut off the metabolic shift and increase 
ROS levels and depolarized mitochondrial membranes. 
These biochemical events were associated with a 
reversion of the CSC-associated properties of the cells. 
RES also was found to inhibit the CSC properties of the 
cells by activating TP53 and inducing miR-145 and 
miR-200c expression, which are normally down-
regulated in NPC CSCs [85]. 
 
Effects of resveratrol on ovarian cancer 
 
The effects of RES on the induction of ROS has been 
examined in A2780 ovarian CSCs. RES was determined 
to kill A2780 ovarian CSCs in a fashion independent of 
ROS. However, ROS inhibited the self-renewal capacity 
of A2780 ovarian CSCs which could survive the RES 
treatment [86]. 
 
Effects of resveratrol on pancreatic cancer 
 
RES has also been suggested to have anti-cancer effects 
on pancreatic cancer cells. RES inhibited proliferation, 
invasion and metastasis and induced apoptosis in 
pancreatic cancer cells and suppressed proliferation and 
viability of pancreatic CSCs. RES also could 
chemosensitize pancreatic cancer cells and have effects 
on diabetes [87].  
 
Human pancreatic cells which are CD133+, CD44+, 
CD24+, ESA+ and ALDH+ are enriched in pancreatic 
CSCs. They also express higher levels of NANOG, 
OCT-4, NOTCH1, MDR1 and ATP Binding Cassette 
Subfamily G Member 2 (ABCG2) than primary 
pancreatic cells and normal pancreatic tissues. CSCs 
were derived from Kras(G12D) transgenic mice. These 
CSCs also express higher levels of NANOG and OCT-4 
than the cells from control mice. RES was determined 
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to suppress growth and development of pancreatic 
cancer in the Kras(G12D) mice. RES activated caspases 
-3, -7 and apoptosis by inhibiting BCL-2 and XIAP in 
the pancreatic CSCs. RES also inhibited: NANOG, 
SOX-2, c-MYC, OCT-4 and ABCG2 in the pancreatic 
CSCs. Genetic suppression of NANOG by shRNA was 
determined to enhance the effects of RES on pancreatic 
CSCs self-renewal. RES also inhibited pancreatic CSC 
migration, invasion and the expression of genes 
associated with EMT including: ZEB-1, SLUG and 
SNAIL [88].  
 
Resveratrol and thyroid cancer 
 
Combined RES and valproic acid treatment has been 
shown to inhibit the growth, stem cell marker 
expression, aldefluor expression and invasiveness of 
two spheroid thyroid carcinoma CSC lines derived from 
anaplastic thyroid cancers. Although valproic acid is 
predominately used in the treatment of epilepsy and 
bipolar disorder and to prevent migraine headaches, it is 
also being examined for its effects on cancer and is in at 
least 83 clinical trials with various cancer patients. 
Valproic acid may inhibit histone deacetylase and this is 
one of the reasons this drug is being examined in cancer 
settings. RES and valproic acid treatment resulted in an 
increase in thyroid differentiation marker expression 
and apoptosis [89].  
 
Summary of resveratrol 
 
The anti-aging, anti-cancer, anti-neurological effects of 
RES have been examined in many different diseases 
and environments. While there have been many 
beneficial effects postulated to be induced by 
consumption of RES, the concentrations required to 
obtain those health benefits may be high. Although, 
there probably are many beneficial health effects of 
consumption of products rich in RES.  
 
Overview of effects of curcumin 
 
CUR has also been reported to have many beneficial 
health properties ranging from anti-aging, anti-cancer, 
anti-hypertensive, anti-inflammatory and anti-
neurological effects. The world-wide market for CUR is 
predicted to be close to $100 million by 2022 
(http: // www.grandviewresearch.com/industry-analysis/ 
turmeric-extract-curcumin-market).  CUR is commonly 
obtained as an extract from Curcuma longa (Turmeric). 
There are other compounds present in the extract from 
Curcuma longa which are related to CUR, they are 
called Curcuminoids. 60-70% of the turmeric extract 
consists of CUR, 20-27% of the turmeric extract 
consists of demethoxy curcumin and 10-15% of the 
turmeric extract consists of bisdemethoxycurcumin 
[90]. Together these components make up 1-6% of 
turmeric by weight. 
 
Curcumin and aging 
 
CUR may have anti-aging properties. The effects of 
CUR may be mediated, in part, by their effects on 
sirtuins.  High doses of CUR (2.5-10 micromolar) have 
been shown to induce the senescence of cancer cells and 
cells involved in building the vasculature. The effects of 
lower doses of CUR (0.1 and 1 micromolar) on vascular 
smooth muscle (VSMC) and endothelial (EC) cells have 
been examined. VSMCs were not protected from 
replicative senescence or premature senescence induced 
by doxorubicin with low doses of CUR. CUR treatment 
did have some effects on increasing the levels of 
sirtuins. Thus, low doses of CUR could increase sirtuins 
levels in the absence of delaying the senescence of 
VSMCs [91].  
 
The ability of CUR to alter the expression of the 
mitochondrial uncoupling protein 2 (UCP2) in old and 
young rats (UCP2-/- and WT) was determined as this 
protein plays critical roles in regulating ROS 
production. These experiments were performed to 
determine whether dietary CUR has positive effects on 
aging-related cerebrovascular dysfunction by increasing 
UCP2 expression. CUR was determined to reduce ROS 
production in UCP2 WT but not in UCP2-/- aging mice. 
CUR restored the cerebrovascular endothelium-
dependent vasorelaxation that was impaired in the older 
rats. Thus, these studies demonstrated that CUR could 
improve cerebrovascular dysfunction which occurs 
during aging [92].  
 
The effects of CUR and MEL on age-related carbonyl 
content of liver in young and old mice were determined. 
Carbonyl content in the liver is detected at increased 
levels during aging. CUR and MEL treatment decreased 
the carbonyl content found in the livers of both the 
young and old mice [93].   
 
Curcumin and lifespan 
 
In Drosophila models, CUR has been shown to prevent 
the accelerated aging that is normally observed after 
irradiation by reduction of oxidative stress [94]. CUR 
was also shown by a different group to enhance the 
Drosophila reproductive lifespan as well as prolong the 
viability of the offspring [95].  
  
Tetrahydrocurcumin (THC) has been shown to increase 
the life span of certain organisms including: nematodes, 
Drosophila and mice. Interestingly in the nematode 
model, CUR reduced the production of ROS. The 
following genes: odd-skipped-related 1 (osr-1 a 
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transcription factor), dual specificity mitogen-activated 
protein kinase kinase 4 (MAP2K4, sek-1, a 
serine/threonine (S/T)kinase), dual specificity mitogen-
activated protein kinase kinase 1 (mek-1), skinhead-1 
(skn-1 encodes a beta-glucan synthesis-associated 
protein), Ca2+/calmodulin-dependent protein kinase II 
(CaMKII, unc-43, encodes a S/T kinase, Sirtuin2 (silent 
mating type information regulation 2) 2 (sir-2.1),  and 
phosphatidylinositol 3-kinase age-1 (age-1) were 
demonstrated to be responsible for the effects of CUR 
on lifespan in nematodes. In Drosophila, superoxide 
dismutase activity was required for increased lifespan. 
In addition, decreased lipofuscin and malondialdehyde 
levels were required for increased lifespan in 
Drosophila. CUR also upregulated the expression of 
superoxide dismutase (SOD) genes as well as decreased 
the expression of various age-related genes including: 






































protein in Drosophila that induced upon bacterial 
infection), defensin (Def, a protein induced in 
Drosophila in response to fungal infection), Cecropin B 
(CecB, a protein involved in immune response of 
Drosophila) and bactericidal protein diptericin B (DptB, 
a protein involved in survival response of Drosophila) 
[96].  
 
Curcumin and senescence 
 
The effects of CUR on gene expression in cancer-
associated fibroblasts obtained from breast cancer 
patients has been examined. CUR increased the 
expression of the p16INK4A and other tumor suppressor 
proteins. In contrast, CUR decreased the activity of the 
JAK2/STAT3 pathway and many molecules involved in 
cellular growth and metastasis including: stromal cell-
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beta. These effects reduced the levels of alpha-smooth 
muscle actin (alpha-SMA) which was attributed to 
decreased migration and invasion of the cells. CUR 
suppressed Lamin B1 and induced DNA damage-
independent senescence in proliferating but not 
quiescent breast stromal fibroblasts in a p16INK4A-
dependent manner. The CUR-induced senescence was 
determined to occur in the absence of an inflammatory 
secretory phenotype, which was in some cases 
associated with procarcinogenic properties. Thus, CUR 
treatment can result in senescence in stromal fibroblasts 
[97]. An overview of the pleiotropic effects of CUR is 
presented in Figure 2. 
 
Curcumin and memory loss diseases 
 
CUR may be useful in the prevention of AD. AD 
results, in part, from the overproduction and 
accumulation in the brain of Abeta.  CUR has recently 
been shown to suppress memory decline by suppressing 
beta-site amyloid precursor protein cleaving enzyme 1 
(BACE1= Beta-secretase 1, an important gene in AD) 
expression which is implicated in beta-amyoid 
pathology in 5xFAD transgenic mice. CUR was 
determined to suppress synaptic degradation and 
improved spatial learning in the 5xFAD mice [98].   
 
The ability of CUR to affect adiposity and obesity-
associated cognitive impairment has been examined in 
mouse models. CUR was found to decrease adiposity 
and improve cognitive function in a similar fashion as 
CR in 15-month-old mice. The effects of CUR and CR 
were positively linked with anti-inflammatory or 
antioxidant actions [99].  
  
The effects of CUR on the prevention of memory 
decline have been investigated in old mice. These 
studies have focused on the effects of CUR on the 
neuronal nitric oxide synthase (nNOS)/nitric oxide 
(NO) pathway. Treatment of mice with CUR aided the 
memory acquisition ability of old mice. CUR treatment 
increased nNOS expression, acidity and NO 
concentration [100].  
 
CUR also has been shown to have positive effects on 
spatial memory by studies with the Morris water maze 
model with old female rats. In addition, CUR treatment 
had positive effects on the oxidative stress induced by 
aging by analysis of malondialdeyde (MDA), protein 
carbonyl and glutathione levels. CUR treatment resulted 
in decreased levels of MDA [101].  
 
Curcumin and macular degeneration 
 
The effects of CUR  on  age-related  macular  degenera- 
tion (AMD) have been examined in an aging retinal 
pigment epithelial cell (RPE) model. The effects of 
CUR on H2O2-treated RPE cells were determined. CUR 
treatment improved cell viability and decrease both 
apoptosis and oxidative stress [102].  
  
Damage induced by oxidative stress to RPE cells may 
be responsible for the aging of the retina and AMD 
which can lead to irreversible loss of vision in the 
elderly. Patient-derived RPEs were isolated by 
reprogramming T cells from patients with dry-type 
AMD. The cells were induced to become pluripotent 
stem cells (iPSCs) and then they were differentiated 
into RPE cells. Interestingly, the AMD-RPEs had 
decreased abilities to defend against oxidative stress 
which may have been responsible for their 
susceptibility to oxidative damage and AMD. These 
cells have been used in vitro drug screening assays. 
CUR treatment was determined to cause reduction of 
ROS in the AMD-RPEs and protected the cells from 
H2O2-induced cell death by reduction of ROS levels. 
CUR also altered the levels of: PDGF, VEGF, insulin 
like growth factor binding protein 2 (IGFBP-2), heme 
oxygenase 1 (HO1), superoxide dismutase 2 (SOD2), 
and glutathione peroxidase 1 (GPX1). Thus, CUR 
treatment might eventually be useful in the treatment 
of patients with or susceptible to the development of 
AMD [103].  
 
Curcumin and miRs 
 
The effects of many drugs on the expression of various 
miRs is an important area of scientific investigation as 
miRs have been shown to play key roles in both positive 
and negative regulation of gene expression. A diagram of 
some of the effects of CUR on miRs important in TP53-
mediated responses and apoptotic pathways is presented 
in Figure 3. Certain miRs can act as oncogenes and 
stimulate abnormal gene expression while other miRs can 
act  as  tumor  suppressors  and  inhibit  gene  expression. 
Often the promoter regions of miR tumor suppressor 
genes becomes hypermethylated in cancer cells and the 
miR is turned off. Approaches to induce the expression 
of miRs with drugs that induce demethylation are an 
important area of scientific research.  
 
CUR has been shown to regulate miR-21 in various 
types of cancer. miR-21 can have effects on 
PI3K/PTEN/AKT, NF-kappaB, programmed cell death 
protein 4 (PDCD4) and other signaling pathways. CUR 
decreases miR-21 levels by increasing miR-21 
exosomes. CUR also decreases miR-21 expression by a 
transcriptional mechanism by binding the promoter 
region of the miR-21 gene [104].  
 









































Effects of curcumin on bladder cancer 
 
CUR also has been shown to have anti-cancer effects on 
bladder cancer. CUR has been shown to induce the 
expression of the tumor suppressive miR-203 in bladder 
cancer. Normally miR-203 is repressed in bladder 
cancer perhaps due to hypermethylation of its promoter 
region. CUR could induce the demethylation of the 
miR-203 promoter region in bladder cancer cell lines. 
AKT2 and SRC have been determined to be targets of 
miR-203 in bladder cancer and their expression was 
decreased after CUR treatment [105]. In some cancers, 
CUR has been shown to downregulate the expression of 
DNA methyl transferase I (DNMT1) and induce DNA 
hypomethylation [106]. A diagram illustrating the effects 









































Effects of curcumin on brain cancers 
 
Demethoxycurcumin (DMC) has been shown to have 
anti-tumor effects against glioblastoma (GMB). 
Temozolomide (TMZ) is used for treating GMB, 
however, TMZ does not prevent GMB recurrence which 
may be due to the presence of glioma stem cells (GSC). 
The effects of DMC and TMC on the induction of 
apoptosis and cell growth of GSC were examined. 
Combining the two drugs was determined to elicit more 
anti-GSC effects. Some of the effects were determined 
alterations in multiple signaling pathways including: 
JAK/STAT-3 signaling, induction of ROS and 
caspase-3-mediated apoptosis. Addition of DMC prior 
to TMZ treatment was determined to be more effective 
[107].  
Figure  3.  Effects  of  curcumin  on  TP53  and  apoptosis  pathways. An  overview  of  the  effects  of  CUR  on  TP53  and  apoptotic
pathways and the effects of miRs are  indicated. miRs  in magenta font  indicate oncomirs. miRs  in blue font are tumor suppressor miRs.
Red arrows indicate induction of an event; black closed arrows indicate suppression of an event. 
 











































Interestingly, CUR was shown to both inhibit glioma 
cell proliferation and induce glioma cells to form 
spheres which were positive for CD133 and Nestin 
expression [108]. CUR suppressed G1 to S phase 
transition and enhanced the expression of OCT-4, SOX-
2 and SOX-4. The expression of these genes was 
essential for retaining the stemness of the glioma-
initiating cells [108].   
 
Progranulin (PGRN) is a protein involved in regulation 
of cell growth. PGRN is overexpressed in GBM and has 
been shown to promote temozolomide-resistance by 
inducing DNA repair and stemness. PGRN upregulated 











































including: Ataxia telangiectasia mutated (ATM, a S/T 
kinase involved in DNA repair response), breast cancer 
type 1 susceptibility protein (BRCA1, a protein involved 
in DNA repair), PARP, Rad51 (a protein involved in 
DNA repair), X-ray repair cross complementing 1 
(XRCC1) and others. PGRN also upregulated the 
expression of many genes involved in stemness 
including: CD44 and CD133 and others involved in 
drug resistance such as ABCG2. The increased 
expression of these genes was due to their trans-
criptional activation by c-FOS/JUNB present in the AP-
1 transcription factor complex. CUR can down regulate 
AP-1 activity. CUR regulates both AP-1 and PGRN 
activity. Suppression of PGRN inhibited the stemness, 
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temozolomide-resistance and tumor formation of the 
GBM cells and sensitized the cells to temozolomide. 
These results point to the importance of the AP-
1/PGRN pathway in GBM cells and point to the 
usefulness of CUR as an adjuvant in GBM therapy 
[109]. A diagram illustrating some of the effects of 
CUR on chemoresistance in brain cancer is presented in 
Figure 5. 
 
CUR may exert anti-tumor effects on glioblastoma CSC 
by augmenting the apoptotic-inducing effects of 
ceramide. It has been postulated that CUR might also 
increase the effects of the chemotherapeutic drug 
lomustine (an alkylating agent) which is used in second 
line therapy for glioblastoma [110].  
 
miR-21 can also have effects on migration, invasion and 
apoptosis of glioma cells. Migration-prone U251-P10 
and U87-P10 lines were derived from U251 and U87 
parental glioma lines. VEGF and intracellular adhesion 




































the migration prone lines. Similar differences in VEGF 
and ICAM-1 expression were detected in clinical 
samples from patients with high and low grade gliomas. 
The migration prone lines displayed increased 
expression of miR-21 which was also observed in the 
advanced patient samples. A miR-21 mimic enhanced 
the migration properties and anti-apoptotic protein 
expression in the U251 cells.  CUR was determined to 
decrease both miR-21 and anti-apoptotic protein 
expression. CUR also induced proteins associated with 
cell death such as LC3-II and other proteins in U251 
cells. In contrast, in the migration-prone derivative 
lines, such increases in proteins associated with cell 
death were not observed after CUR treatment. These 
studies point to the importance of miR-21 in migration 
and survival of glioma cells [111].  
  
CUR treatment of U-87 glioblastoma cells resulted in 
miR-146A expression which was determined to be 
involved in the CUR-mediated enhancement of 
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temozolomide treatment resulted in enhanced toxicity in 
U-87 glioblastoma cells. The expression of miR-146a 
was determined to be necessary for the enhanced 
toxicity. Overexpression of miR-146a resulted in 
decreased NF-kappaB activation on temozolomide-
treated cells. Suppression of NF-kappaB activity 
enhanced temozolomide-induced apoptosis. These 
studies point to a mechanism by which CUR can 
sensitize glioblastoma cells to temozolmide, induction 
of miR-146a and suppression of NF-kappaB activity 
[112].  
 
The effects of CUR encapsulated in a nontoxic 
nanocarrier, called dendrosomes have been examined 
on U87MG glioblastoma cells. Dendrosomal curcumin 
increased the expression of miR-145 and decreased the 
expression of stemness genes including: NANOG, 
OCT4A, OCT4B1, and SOX2 [113]. A diagram of 
some of the effects of CUR on pathways involved in 





































Effects of curcumin on breast cancer cells 
 
CUR has been shown to have effects on drug 
transporter expression in breast cancer cells with CSC 
properties. CUR could increase the tumoricidal effects 
of mitomycin C by suppressing ABCG2 expression. In 
these studies, CUR could also increase the sensitivity of 
MCF-7 and MDA-MB-231 cells to various chemo-
therapeutic drugs including: cisplatin, doxorubicin and 
paclitaxel. The combination of CUR and mitomycin C 
together prevented the sphere forming capacity of 
MCF-7 and MDA-MB-231 cells after five passages. 
These effects were only observed when both drugs were 
added together. The effects of CUR on the sphere 
forming capacity of the breast cancer cells were 
determined to be dependent primarily upon ABCG2 
expression [114].  
 
CUR has been shown to affect microtentacles (McTN) 







































pathways  involving  stemness, microenvironment  and  EMT  pathways  and  the  effects  of miRs  are  indicated.  Red  arrows  indicate
induction of an event; black closed arrows indicate suppression of an event. 
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McTN are tubulin-based protrusions present in detached 
cells. McTN may be involved in cell adhesion and 
attachment and have been hypothesized to be involved 
in metastasis. CUR was shown to affect the McTNs and 
prevented reattachment [115].  
 
Treatment of breast stromal fibroblasts with CUR was 
determined to increase the level of both p16INK4A 
mRNA and miR-146b-5p. miR-146b-5p suppressed IL-
6 levels in a p16INK4A-dependent fashion. This resulted 
in a reduction of the paracrine pro-carcinogenic effects 
of the breast stromal fibroblasts which can stimulate 
EMT in breast cancer cells in a paracrine fashion. miR-
146-5p binds a region in the 3’UTR of the IL-6 mRNA 
and suppresses it function. In contrast, suppression of 
miR-146b-5p results in activation of breast stromal 
fibroblasts [116].  
 
Bisphenol A (BPA) is used in the manufacture of 
plastics such as water bottles. BPA may be important in 
breast cancer development as it is an endocrine 
disrupter. The ability of CUR to protect against the 
detrimental effects of BPA is not clear. BPA can have 
estrogenic-like effects on ER+ MCF-7 cells and 
increase their proliferation. CUR was shown to inhibit 
the effects of BPA on the breast cancer cells. BPA 
induced the expression of oncogenic miR-19a and 
miR19b. BPA has effects on the expression of PTEN 
and pAKT, pMDM2, TP53, and PCNA which are 
growth promoting. These effects that BPA had were 
reversed upon CUR treatment [117].  
 
Emodin is a compound present in the root and rhizome 
of the Rheum palatum plant. The effects of emodin and 
CUR have been examined on breast cancer cells. A 
synergistic interaction was observed when emodin and 
CUR were combined in terms of inhibition of cell 
growth, survival and invasion. miR-34a expression was 
upregulated by emodin and CUR. miR-34a can decrease 
the expression of BCL-2 and BMI1 [118].  
  
The effects of CUR on MCF-7 breast cancer cells have 
been examined. CUR was shown to inhibit BCL-2 
expression by increasing miR-15a and miR-16 in MCF-
7 cells. Silencing miR-15a and miR-16 increased the 
expression of BCL-2 expression [119].  
 
Effects of curcumin on colorectal cancers (CRC) 
 
CUR has been shown to target CRC CSC. The effects 
of CUR can be enhanced by various anti-cancer agents. 
CUR may act as a chemosensitizer and target multiple 
signaling pathways including: WNT/beta-catenin, 
sonic hedgehog (SHH), NOTCH and PI3K/PTEN/Akt/ 
mTORC and have effects on EMT and regulation of 
miRs. Cur may influence CRC CSC [120].  
CUR has been shown to interact with the CD44 (a 
receptor for hyaluronic acid) and stimulate apoptosis in 
CRC CSC. While CUR induced some apoptosis in both 
CRC cancer cells and CRC CSCs, CUR induced more 
apoptosis in CRC CSCs. The authors proposed that 
CUR may interact with CD44+ at the cell membrane 
and block the entry of glutamine into the cells [121].  
 
The effects of CUR have been recently examined on 
patient-derived colorectal liver metastases (CRLM). 
The ability of CUR to augment FOLFOX treatment was 
determined first in CRC CSC models and then in a 
phase I dose escalation study. Interestingly treatment 
with CUR alone and CUR in combination with 
FOLFOX reduced CRLM sphere forming numbers. 
CUR also reduced the number of cells with high 
aldehyde dehydrogenase activity (ALDH(high)/CD133 
(-) phenotype. CUR was determined to be safe and well-
tolerated in combination with FOLFOX chemotherapy 
in the clinical trial with twelve CRLM patients [122].   
 
Doublecortin-like kinase 1 (DCLK1) is an important 
kinase in the doublecortin kinase family which have 
multiple neurological functions and has also been 
implicated in stem cells. CUR is normally thought to 
induce apoptosis in cancer cells by multiple mechanisms. 
Recently, CUR has been determined to promote the 
survival of DCLK1+ CRC CSCs by inducing autophagy. 
CUR was determined to reduce the expression of 
DCLK1/CD44/ALDHA1/LGR5/NANOG in CRC CSC 
three-dimensional spheroid cultures as well as in tumor 
xenografts. Surprisingly, CUR also promoted autophagic 
survival of some DCLK1-positive CSCs. Suppression of 
DCLK1 induced apoptosis and prevented the pro-
survival effects of CUR in the subset. These authors 
suggested that suppression of DCLK1 may enhance the 
effects of CUR on certain CRC CSC subsets [123].  
 
CDF can induce miR-34 which is normally silenced in 
CRC. miR-34a and miR-34c were determined to be 
down-regulated in CRC patient samples compared to 
normal colonic mucosa. The decreased expression of 
these miRs is believed to be due to promoter hyper-
methylation as treatment with 5-AzaC induces their 
expression. CDF also induced the expression of these 
miRs which suppressed NOTCH1 [124]. A diagram of 
some of the effects of CUR on suppression of CRC 
chemoresistance is presented in Figure 7. 
 
The effects of 5-FU and CUR on DNA mismatch repair 
(MMR) status in CRC CSCs have been examined. 
These studies employed 3D cultures of HCT116, 
HCT116+ch3 (+ chromosome 3) and 5FU-resistant 
clones cultured in the presence and absence of CUR. 
These studies demonstrated that pre-treatment of the 
resistant cells with CUR increased the effects of 5FU 
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and resulted in the disintegration of colonospheres and 
apoptosis. A combination of CUR and 5FU was 
determined to affect MMR-deficient CRC cells more 
effectively than MMR-competent cells [125].  
 
The effects of CUR and 3 acetyl-11-keto-β-boswellic 
acid (AKBA) have been investigated on CRC cells. The 
expression of both miR-27a and miR-34a were both 
altered in CRC cells after CUR or AKBA treatment 
[126]. ROS have been proposed to be responsible for 
the ability of curcuminoids to suppress drug resistance 
of SW-480 CRC cells. This is believed to occur by 
disruption of miR-27a/zinc finger and BTB domain 
containing 10 (ZBTB10) signaling. Curcuminoids were 
prepared in this study by HPLC. Their effects were 
examined on CRC cell lines SW-480 and HT-29 cells 
and normal CCD-18Co colon fibroblast cells.  The 
curcuminoids were shown to affect the CRC HT-29 and 
SW-480 cell lines but not the normal colon fibroblast 
cells. The curcuminoids enhanced the effects of 5FU on 




































has been shown to down-regulate the expression of 
miR-27a in CRC cells. This may occur by CUR 
inducing ROS which results in suppression of 
specificity protein expression (SP1, SP3 and SP4) as 
well as miR-27a. The ZBTB10 gene is normally a target 
of miR-27a and upon downregulation of miR-27a by 
CUR, increased expression of ZBTB10 occurred. 
ZBTB10 is a transcriptional repressor of SP expression. 
CUR suppressed SP1 and SP3 expression which in turn 
led to decreased MDR1 expression and decreased drug 
resistance [127-129].  
 
FBXW7 (F-box and WD repeat domain-containing 7) is 
a tumor suppressor which is an E3-ubiquitin ligase 
involved in the ubiquitination of many growth related 
proteins. FBXW7 is regulated by many molecules e.g., 
TP53 and miRs e.g., miR-27a. FBXW7 is frequently 
mutated in CRC [130]. Deletions of TP53 and FBXW7 
may be involved in the progression of CRC from 
adenoma to carcinoma at least in animal models [131]. 
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CRC, the combination of CUR and AKBA showed 
greater effects in TP53- CRC and this was determined 
to involve FBXW7. Treatment of TP53- cells with CUR 
and AKBA resulted in increased FBXW7 expression as 
well as downregulation of its target genes [131]. 
 
CRC colonospheres have been determined to have 
elevated miR-21 but decreased PTEN expression. CDF 
downregulated the expression of miR-21 in chemo-
resistant HCT116 and HT-29 cells. Moreover, PTEN 
levels were restored and inhibited activated Akt 
expression after CDF treatment [132].  
 
The transcriptional start sites of the miR-21 gene were 
identified in Rko and HCT116 cells. PMA was shown 
to induce the expression of miR-21 via AP-1 sites in the 
promoter region. CUR suppressed the binding to AP-1 
to the miR-21 promoter region. The expression of the 
tumor suppressor PDCD4 was induced as it is a target 
of miR-21[133].  
  
Certain chemotherapy-resistant CRC cells have elevated 
levels of miR-21. These chemoresistant cells are 
enriched with cells with CSC phenotypes. One marker 
associated with CRC CSCs is CD44.  Suppression of 
miR-21 decreased the presence of cells with the CSC 
phenotype in HCT-116 and HT-29 CRC cells. The 
effects of CDF, FLUFOX and the CDF + FULFOX 
combination were examined on these cells. Induction of 
differentiation increased the sensitivity of the CRC CSC 
to the above-mentioned treatment. The growth 
inhibition properties were greater in the CDF or CDF + 
FLUFOX treated cells. Treatment of differentiating 
cells with CDF or CDF + FLUFOX combination 
reduced the expression of CD44 and EGFR [134].  
 
Effects of curcumin on cervical cancer 
 
CUR and stattic both inhibit STAT3 in papillomavirus-
induced cervical cancer SiHa cells. Reduction of 
STAT3 expression resulted in a decrease in miR-21 
expression. In contrast, specific depletion of miR-21 
resulted in an increase in PTEN levels which is a 
negative regulator of STAT3. Restoration of Let-7a also 
resulted in a reduction of STAT3 levels. Suppression of 
the papillomavirus E6 activity resulted in increased Let-
7a but decreased miR-21 levels and led to increased 
PTEN and decreased STAT3 levels. These studies point 
to the interactions between CUR, E6, miR-21, Let-7a, 
PTEN and STAT3 in palillomavirus-induced cervical 
carcinogenesis [135].  
 
Effects of curcumin on esophageal cancer 
 
CUR inhibits the growth of esophageal cancer cells by 
suppression of NOTCH signaling. CUR induced 
apoptosis in the esophageal cells which was associated 
with caspase-3 activation, an increase in the ratio of 
BAX/BCL-2 and a decrease in cyclin  D1 levels. CUR 
also decreased sphere formation in the esophageal cells, 
suppressed NOTCH activation and JAGGED1 and HES 
expression. The reduction of NOTCH expression was 
associated with decreased gamma-secretase complex 
activity. CUR treatment decreased the expression of 
miR-21 and miR-34a. In contrast, curcumin treatment 
upregulated tumor suppressor let-7a miRNA [136].   
 
Effects of curcumin on head and neck cancers 
 
The ability of CDF, packaged in liposomes, to inhibit 
HNSCC growth has been determined recently on 
cisplatin-resistant HNSCC cell lines. The liposomal-
CDF was determined to inhibit proliferation, tumor 
formation and CD44 expression in the cisplatin-resistant 
CCL-23R and UM-SCC-1R HNSCC lines. These 
studies suggest that liposomal-CDF may be an approach 
to deliver CDF to cisplatin-resistant HNSCC tumors 
[137].  
 
CUR treatment has been shown to induce miR-145 
promoter activity in head and neck squamous cell 
carcinomas (HNC). This resulted in decreased SOX9 
expression. SOX9 can normally induce ADAM metallo-
peptidase domain 17 (ADAM17) expression. Thus, the 
induction of miR-145 by CUR-inhibited SOX9 and 
ADAM17 expression which are important in the 
generation of HNC CSCs [138].  
 
Effects of curcumin on HCC 
 
CUR has been shown to produce significant growth 
inhibitory and apoptotic effects in human HCC cells 
that expressed constitutively-activated NF-kappaB. This 
was determined to be due, in part, to ROS generation 
and mainly dependent on activation of caspase-9 and -3. 
In addition, CUR used in combination with cisplatin 
resulted in a synergistic cytotoxic effect, while the 
effects were additive or sub-additive in combination 
with doxorubicin [139]. A diagram of the effects of 
CUR on HCC is presented in Figure 8.  
 
NF-kappaB signaling is one of the key pathways 
frequently activated in liver CSCs [140]. It was recently 
shown that treatment of CUR-sensitive HCC CSCs with 
CUR selectively reduces the number of CSCs as 
evidenced by a reduced side positive (SP) staining, 
down-regulation of CSC markers, decrease in sphere 
formation, and suppressed tumorigenicity. Conversely, 
the CUR-resistant cells show a paradoxical increase in 
the proliferation and expression of CSC markers. In 
terms of the molecular mechanism, an important 
component of the CUR-mediated CSC-depletion was 
www.aging‐us.com  1499  AGING 
attributed to NF-kappaB-mediated HDAC inhibition. 
Consistently, the combination CUR and trichostatine, an 
inhibitor of class I/II HDAC, has been shown to 
sensitize resistant cells to CUR [141].  
 
Some of the effects of CUR treatment are inhibition of 
NF-κB activity and downstream effector proteins, 
including: VEGF, MMP-9, XIAP, BCL-2 and Cyclin-
D1. This was demonstrated to sensitize the HCC cells to 
radiation [142]  
 
Piperine is an alkaloid found in the seeds of black 
pepper (Piper nigrum) and is known to enhance the 
bioavailability of several therapeutic agents, including 
CUR [143]. Recently, it was demonstrated that co-
administration of CUR with piperine resulted in a 
significant protection against diethylnitrosamine 
(DENA)-induced hepatocellular carcinoma in rats in 
comparison with CUR by itself [144].  
 
CUR inhibits HIF-1 in certain HCC cell lines and in 



































occur by CUR inducing the degradation of the aryl 
hydrocarbon receptor nuclear translocator (ARNT). 
HIF-1 and ARNT normally form a complex and CUR 
prevented this complex from forming. CUR was 
demonstrated to induce the proteasomal degradation of 
ARNT via oxidation and ubiquitination [145]. CUR also 
inhibited EMT by suppressing HIF-1alpha activity in 
HepG2 cells [146].   
 
Phthalates are chemicals added to plastics and they are 
referred to as plasticizers [147]. They serve to increase 
the durability, flexibility, longevity and transparency of 
plastics. They also may have adverse effects on human 
health as they may promote cancer development. The 
bis(2-ethylhexyl) phthalate has recently been shown to 
stimulate migration, invasion and EMT in HCC. bis(2-
ethylhexyl) phthalate also increased the presence of 
HCC CSCs, stemness and growth and metastasis in 
animal studies. CUR was shown to suppress these 
properties of bis(2-ethylhexyl) phthalate through 
inhibition of  the aryl  hydrocarbon  receptor/ERK/SK1/ 






































www.aging‐us.com  1500  AGING 
MEG3 encodes a lncRNA which is a tumor suppressor. 
There is decreased expression of the MEG3 lncRNA in 
HCCs. The decreased expression of MEG3 is believed 
to be due to promoter methylation. CUR has been 
shown to alter the DNA methylation status. The effects 
of CUR on DNA methylation may be carried out by 
DNMT1, DNMT3A and DNMT3B. miR-29a was 
determined to inhibit DNMT3A and DNMT3B and 
miR-185 was shown to affect DNMT1. When DNMT1, 
DNMT3A and DNMT3B were decreased by dendro-
somal CUR treatment, increased expression of MEG3 
occurred which was due to elevated expression of miR-
29a and miR-185. Thus, dendrosomal curcumin can 
result in DNA hypomethylation and expression of 
previously silenced tumor suppression genes that may 
be important in HCC [149, 150].  
 
The expression of miR-200 family members was 
examined in HepG2 and HepJ5 HCC cell lines. HepG2 
cells expressed higher levels of miR-200a/b and were 
more resistant to CUR than HepJ5 cells. Overexpression 
of miR-200a/b conferred resistance to CUR in HepJ5 
cells [151].  Thus, targeting miR-200a/b may overcome 
CUR-resistance.  
  
The core protein of HCV has been shown to inhibit the 
apoptosis normally induced by CUR in Huh7 HCC 
cells. The core protein of HCV normally induces miR-
345 which targets and suppresses p21Cip-1 [152].  
 
CUR has a poor solubility in aqueous enviroment, and 
consequently it has a low bioavailability and therefore 
low concentrations at the target sites. To overcome 
these limitations, various types of nanoparticles have 
been developed to delivery CUR to targets either alone 
or in combination with other drugs, such as sorafenib 
and doxorubicin [153-155]. This approach has provided 
a promising strategy to enhance CUR antitumor effects 
on HCC in vitro and in vivo. 
 
Effects of curcumin on leukemia and lymphoma 
 
Malignant T cells display decreased expression of miR-
22 in comparison to normal T cells. STAT5 has been 
shown to bind to the promoter region of miR-22. 
Suppression of the Jak3/STAT3/STAT5 resulted in an 
increase in pri-miR-22 and subsequently miR-22. 
Histone deacetylase inhibitors (HDACi) also stimulate 
miR-22 expression. CUR inhibited Jak-3 activity and 
stimulated miR-22 expression. In these studies, miR-22 
was determined to have many effects such as inhibition 
of: cyclin dependent kinase 2 (CDK2), histone 
deacetylase 6 (HDAC6), MYC associated factor X 
(MAX), MYC binding protein (MYCBP), nuclear 
receptor coactivator 1 (NCOA1), and PTEN. These 
genes have previously been implicated in cutaneous T-
cell lymphoma (CTCL) [156].  
  
Histone modifying enzymes have been shown to be 
regulated by CUR and miR-34. Histone modifying 
enzymes play key roles in regulation of gene expression 
because they regulate the accessibility of promoter 
regions present in genes contained in chromatin to 
transcription factors. The regulation of the histone 
modification genes was examined in pediatric acute 
lymphoblastic leukemia (ALL). The expression profile 
of the histone modification genes was different from 
normal control samples. The histone deacetylases 
HDAC2 and PAK1 were upregulated in the ALL 
samples while other genes including PRMT2 and the 
putative tumor suppressor EP300 were downregulated. 
Ingenuity Pathway Analysis revealed that CUR and 
miR-34 could be regulators of the histone-modifying 
genes in ALL [157].  
  
CUR treatment has been shown to induce promoter 
demethylation of the p15 gene (CDKN2B cyclin 
dependent kinase inhibitor 2B, pINK4B) in RAJI ALL 
cells. This resulted in the induction of apoptosis in these 
cells [158].  
  
miR-368 is involved in regulation of DNA damage 
repair. miR-368 is upregulated in terminally-
differentiated cells. miR-368 is involved in regulating 
the sensitivity of leukemia cells to chemotherapeutic 
drugs such as cisplatin. The structural maintenance of 
chromosome 1A (SMC1A) is a target of miR-658. 
Increased expression of miR-658 elevated the 
sensitivity of certain leukemia cells to cisplatin. miR-
638 was demonstrated to inhibit the recruitment of 
H2AX to DNA break sites [159].  
 
Effects of curcumin on BCR-ABL-transformed 
leukemia models 
 
The ability of a CUR derivative (C817) to inhibit the 
growth of imatinib-resistant chronic myeloid leukemia 
(CML) cell lines has been determined. C817 could 
suppress the proliferation of imatinib-resistant murine 
32D cells which had mutant BCR-ABL genes 
(nucleotide binding P-loop mutants Q252H, Y253F, and 
imatinib contact residue mutant T315I) or imatinib-
resistant human erythroleukemia K562/G01 cells with 
amplified WT BCR-ABL genes. C817 was determined 
to inhibit BCR-ABL kinase activity in imatinib-resistant 
cells with mutant and WT BCR-ABL in the low 
nanomolar range. C817 inhibited BCR-ABL, STAT-5 
and CRKL phosphorylation in imatinib-resistant cells. 
C817 may also suppress leukemia progenitor/stem cells 
[160].  
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CUR also has been shown to inhibit CML growth by 
exosomal disposal of miR-21. Exosomes can contain 
miRs and proteins and other cellular components which 
can be released by cells and influence the proliferation 
of other cells. CUR treatment has been shown to result 
in activation of PTEN, which is a target of miR-21. In 
contrast, CUR treatment resulted in a decrease of VEGF 
and activated Akt. The presence of miR-21 in exosomes 
from K562 and LAMA84 cells after CUR treatment was 
determined. CUR treatment also resulted in an increase 
of miR-196b which lead to decreased levels of BCR-
ABL expression. The size of CML xenografts in mice 
was smaller in CUR-treated SCID mice than in controls. 
Exosomes from CUR-treated cells were enriched with 
miR-21 compared to controls. These results indicate a 
mechanism by which CUR may elicit anti-tumor effects 
in CML [161].  
 
CUR has been shown to induce the expression of miR-
21 in CML. miR-21 has been detected in tumor derived 
exosomes and was shown to affect the angiogenic 
phenotype. The miR-21 present in the CML-derived 
exosomes was shuttled into endothelial cells. When 
HUVEC cells were exposed to CML-derived exosomes, 
increases in IL-8 and vascular cell adhesion protein 1 
(VCAM1) were observed. However, in HUVEC cells 
treated with exosomes derived from CML cells that had 
been exposed to curcumin, these increases in IL-8 and 
VCAM1 were not detected and reduced RAS homolog 
family member B (RHOB) expression and mobility was 
observed. Thus, the CUR-derived exosomes were 
suppressing angiogenesis [162].  
 
Effects of curcumin on lung cancer cells 
 
CUR has been determined to suppress the tumor sphere 
formation capacity in lung cancer H460 cells by 
suppressing the JAK2/STAT3 signaling pathway. CUR 
also suppressed lung cancer xenograft formation in 
mouse studies [163].  
 
CUR is postulated to exert its effects on cancer via 
multiple mechanisms including more than one 
mechanism at the same time. It may have anti-
angiogenic, anti-oxidant, immunomodulatory and pro-
apoptotic effects. Recently in lung cancer cells, CUR 
has been shown to alter the expression of enhancer of 
zeste homolog 2 (EZH2), by both transcriptional and 
post-transcriptional mechanisms. CUR also suppressed 
EZH2 expression by induction of miR-let 7c and miR-
101. The expression of NOTCH1 was inhibited upon 
EZH2 suppression [164].  
 
CUR has been shown to activate the TP53/miR-192-
5p/miR-215/XIAP pathway in NSCLC. CUR activated 
both miR-192-5p and miR-215 in TP53 WT A427 cells. 
miR-192-5p and miR-215 functioned as tumor 
suppressors in these cells. Conditional knockdown of 
TP53 in TP53 WT H460, A427 and A549 cells 
abrogated the effects of CUR. Expression of WT TP53 
in TP53-mutant H1299 resulted in miR-192-5p and 
miR-215 expression after CUR treatment. The effects of 
CUR were shown to be dependent on miR-192-5p and 
miR-215 expression. These studies revealed that the X-
linked inhibitor of apoptosis (XIAP) was a novel 
transcription target of miR-192-5p and miR-215 in non-
small cell lung cancer [165].  
 
CUR can also suppress proliferation and induce 
apoptosis in NSCLC via suppression of the 
PI3K/PTEN/Akt pathway. This was shown to be 
mediated by CUR inducing miR-192-5b expression in 
A549 cells. Increased miR-192-5b expression in A549 
cells resulted in decreased proliferation and increased 
apoptosis while suppression of miR-192-5b had the 
opposite effects. CUR increased miR-192-5p expression 
while it decreased PI3K/PTEN/Akt activity. miR-192-
5p mimic could increase the effects of CUR [166].  
 
CDF elicits enhanced anti-cancer activity. CDF 
inhibited MMP2 expression more effectively in A549 
and H1299 cells than CUR. CDF increased the 
expression  of   miR-874  which  targets  MMP-2  [167].   
The effects of CUR on miR-21 expression in NSCLC 
A549 cells were determined. CUR treatment resulted in 
suppression of miR-21 and an increase in PTEN which 
is a target of miR-21 [168].  
 
CUR has been shown to increase the effectiveness of 
chemotherapy on the CD166+/EpCAM+CSC 
subpopulation in two NSCLC cell lines (A549 and 
H2170). This was ascertained by determining the extent 
of cisplatin-induced apoptosis and inhibition of 
metastasis after CUR treatment. CUR decreased Cyclin 
D1 expression and increased p21Cip1 expression. CUR 
also stimulated the intrinsic apoptotic pathway as 
APAF1 and Caspase-9 were activated in the 
CD166+/EpCAM+ CSC subpopulation of A549 cells. 
These studies have revealed that CUR may enhance the 
effects of cisplatin on NSCLC CSCs [169].  
 
The effects of CUR on A549 lung cancer cells were 
further examined. miR-186 was determined to be down-
regulated by CUR treatment of A549 cells. Caspase-10 
was determined to be a target of miR-186 [170]. In 
these studies, with miR-186 and lung cancer, miR-186 
appears to have promoted growth and suppression of 
miR-186 results in apoptosis and drug resistance. CUR 
appears to decrease miR-186 expression. 
 
The effects of CUR have been examined on multidrug-
resistant human lung adenocarcinoma A549/DDP cells. 
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CUR treatment also decreased the expression of miR-
186 in these cells. Overexpression of miR-186 
suppressed the effects of CUR on the drug-resistant 
cells. Treatment of the cells with a miR-186 inhibitor 
induced apoptosis of the cells [171].  
 
miR-346 is an oncomir for NSCLC. It can affect cell 
growth and metastasis. The xeroderma pigmentosum 
complementation group C (XPC) gene is involved in 
nucleoside excision repair and is a target for miR-346 
[172].  
 
Effects of curcumin on melanoma 
 
Diphenyl difluoroketone (EF24) is another CUR analog. 
EF24 can arrest cell cycle progression, induce 
apoptosis, inhibit mobility and EMT in melanoma cells 
and prevent their metastasis in vivo. EF24 can induce 
miR-33b which binds and inhibits high-mobility group 
AT-hook 2 (HMGA2) expression in Lu1205 and A375 
melanoma cells. HMGA2 is a protein which may be 
present in the enhanceosome and is a transcriptional 
regulatory factor. HMGA2 may stimulate the expres-
sion of genes by altering chromatin structure. EF24 
treatment resulted in increased E-cadherin and 
decreased N-cadherin, vimentin and STAT3 
phosphorylation [173].   
 
The effects of a diet consisting of 4% CUR on mice 
injected with B78H1 murine melanoma cells were 
determined. Mice fed the diet containing 4% CUR had 
reduced growth of the melanoma compared to the 
control mice. RNA analysis indicated that miR-205 was 
elevated over 100-times in the mice fed the CUR diet. 
BCL-2 and PCNA were down regulated in the mice fed 
the CUR diet [174].  
 
Effects of curcumin on nasopharyngeal carcinoma 
 
CUR inhibited the expression of miR-125-5p, miR-574-
3p and miR-210 in undifferentiated nasopharyngeal 
carcinoma (NPC). In contrast, forced expression of 
miR-125-5p stimulated proliferation, migration and 
invasion of HONE1 cells. miR-125-5p was determined 
to be detected at higher levels in NPC than in healthy 
controls. miR-125-5p inhibited TP53 expression. CUR 
was determined to inhibit miR-125-5p but increase 
TP53 expression [175].  
 
The Ewing Sarcoma associated transcript (EWSAT1) is 
a long non-coding RNA. It is expressed in NPC. 
Recently EWSAT1 was determined to be upregulated in 
NPC tissues and associated with poorer survival. 
EWSAT1 upregulated the expression of Cyclin D1 by 
acting as a competitive “sponge” for miR-326/330-p5 
clusters. Thus, by sponging miR-326/330-p5, Cyclin D 
was detected at higher levels [176].  
 
Effects of curcumin on oral cancer 
 
CUR regulated the expression of miR-9 in oral 
squamous cell carcinoma (OSCC). The levels of miR-9 
were significantly lower in clinical OSCC patient 
samples than in adjacent non-tumor specimens. 
Suppression of miR-9 by anti-miR-9 oligonucleotides 
prevented the effects of CUR on growth suppression 
and re-activated WNT/beta-catenin signaling [177].  
  
miR-31 is upregulated and acts as an oncogene in 
OSCC. EGF activation of EGFR signaling in OSCC 
results in the increased expression of miR-31, miR-181b 
and miR-222 expression. Inhibition of AKT or 
knockdown of C/EBPbeta suppressed miR-31 up-
regulation. CUR treatment inhibited AKT activation, 
upregulation of C/EBPbeta and miR-31 [178]. 
 
Effects of curcumin on osteosarcoma 
 
CUR has also been shown to suppress proliferation and 
invasion of the human osteosarcoma cell line MG-63. 
This was shown to occur by CUR inducing miR-138 
expression. mRNAs encoding SMAD4, NF-kappaB p65 
and Cyclin D3 are targets of miR-138 and they were 
suppressed by miR-138 after CUR treatment. In 
contrast, inhibition of miR-138 was shown to increase 
the expression of SMAD4, NF-kappaB p65 and Cyclin 
D3. A diagram of the effects of CUR on invasion and 
metastasis is presented in Figure 9 [179].  
 
Effects of curcumin on ovarian cancer 
 
CUR treatment has been determined to result in an 
increase in miR-9 expression in SKOV3 ovarian cancer 
cells. Inhibition of miR-9 expression prevented the 
growth inhibitory effects of CUR while overexpression 
of miR-9 increased cleavage of caspase-3, PARP and 
apoptosis. Both CUR treatment and overexpression of 
miR-9 resulted in decreases in phosphorylation of Akt 
and FOXO1 [180]. Recently the effects of HCC 
formulated in nanoparticle has been shown to be more 
effective in suppressing the proliferation of certain 
ovarian cancer cell lines than administration of CUR by 
itself [181].  
 
Effects of curcumin on pancreatic cancer cells 
 
CD44 has been implicated in the MDR of pancreatic 
cancer cells. Approaches to target CD44 may eventually 
be appropriate for treatment of drug-resistant pancreatic 
cancers. Hyaluronic acid (HA) targeting may be an 
approach to suppress drug resistant pancreatic cancers.  








































Recently, the HA conjugate of copoly(styrene maleic 
acid) (HA-SMA) has been used to make nanomicelles 
with CDF and is referred to as HA-SMA-CDF. The 
effects of these HA-SMA-CDF nanomicells on the 
MIA-PaCa-2 and AsPC1 pancreatic cancer cells have 
been examined. The HA-SMA-CDF nanomicells were 
shown to elicit stronger anti-cancer responses against 
CD44+/CD133+/EpCAM+ CSCs compared with 
CD44-/CD133-/EpCAM- cells. The HA-SMA-CDF 
nanomicelles inhibited NF-kappaB expression which is 
important in proliferation and invasion and other 
properties associated with tumor development [182].  
 
miR-7 has been shown to be regulated by CUR in 
pancreatic cancer cells. CUR suppressed growth of pan-
creatic cancer cells. The histone lysine methyltransferase 








































crease miR-7 and decrease SET8 expression [183].  
 
The expression of miR-146a has been examined in 
pancreatic cancer patient samples.  miR-146a was 
detected at lower levels in approximately 80% of 
pancreatic cancer samples as opposed to non-cancerous 
tissues. One of the targets of miR-146a is EGFR. 
Treatment with the modified CUR, CDF, resulted in the 
re-expression of miR-146a which inhibited EGFR 
expression. Re-expression of miR-146a or treatment 
with CDF inhibited tumor xenografts as well as reduced 
EGFR, ERK1, ERK2, and KRAS expression. 
Knockdown of miR-146a in the pancreatic AsPC-1 cell 
line resulted in increased EGFR expression and 
enhanced clonogenic growth. Suppression of EGFR or 
ectopic expression of pre-miR-146a inhibited the 
invasive properties of the cells [184].  
Figure 9. Overview of  effects of  curcumin on HIF‐1alpha, miRs  and metastasis. An  overview  of  the  effects  of  CUR  on
pathways  involving migration,  invasion  and metastatic  pathways  are  indicated. Red  arrows  indicate  induction  of  an  event;  black
closed arrows indicate suppression of an event. 
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CDF induced the expression let-7a, b, c, d miRs, miR-
26a, miR-101, miR-146a, and miR-200b, c in pancreatic 
cancer. These miRs are normally silenced in pancreatic 
cancer. In contrast, CDF repressed the expression of the 
histone methyltransferase EZH2 and EpCAM. In an 
orthotopic pancreatic tumor model, CDF also inhibited 
the expression of EZH2, NOTCH-1, CD44, EpCAM, and 
NANOG. In in vitro cell lines assays, CDF increased 
expression of let-7, miR-26a, and miR-101 [185].  
 
The expression of the miR-200 family, PTEN and 
membrane type-1 matrix metalloproteinase (MT1-
MMP) has been examined in pancreatic cancer cell 
lines. Loss of expression of miR-200a, miR-200b and 
miR-200c was associated with decreased PTEN 
expression and increased expression of MT1-MMP. The 
synthetic analog CDF induced the re-expression of the 
miRs and PTEN while MT1-MMP was decreased in 
BxPC-3, MIA-PaCa-2 and gemcitabine-resistant MIA-
PaCa-2-GR cells as was as cell growth [186].  
  
CDF could inhibit sphere formation capacity of 
pancreatic cancer cell lines and inhibit the expression of 
the CSC markers CD44 and EpCAM. CDF also 
inhibited xenograft formation and decreased NF-
kappaB activity, miR-21 and COX levels and increased 
PTEN and miR-200 levels [187].   
  
Gemcitabine is a nucleoside analogue which is used in 
pancreatic and other cancer therapies. CUR inhibits 
tumor growth but its effects are limited due to its poor 
bioavailability. The effects of CDF have been examined 
in gemcitabine-sensitive and gemcitabine-resistant 
pancreatic cancer cell lines. Downregulation of AKT, 
COX2, prostaglandin E2 (PEG2), VEGF, and NF-
kappa-B activity was observed after CDF treatment. 
The effects of CDF on miR-200 and miR-21 were 
analyzed. CDF increased the expression of miR-200 and 
decreased the expression of miR-21 which resulted in 
increased PTEN protein levels [188].  
 
The expression of miR-221 has been shown to be 
elevated in pancreatic cancer cells compared to normal 
pancreatic duct epithelial and tissue. In addition, 
pancreatic cancer patients with high miR-221 
expression had a shorter survival in comparison with 
patients which had lower miR-221 expression. 
Inhibition of miR-221 resulted in a decrease in pro-
liferation and increased expression of: PTEN, p27Kip1, 
p57Kip2 and PUMA which are likely targets of miR-221. 
The effects of isoflavone mixture (G2535), formulated 
3,3'-diindolylmethane (BR-DIM), and CDF were 
examined on MIA-PaCa-2 and PANC21 cells. 
Treatment with these compounds decreased the levels 
of miR-221 and increased the levels of: PTEN, p27Kip1, 
p57Kip2 and PUMA [189].  
Effects of curcumin on prostate cancer cells 
 
CUR has been shown to have some effects on signaling 
pathways implicated in prostate cancer [190]. CUR has 
been shown to have effects on cancer associated 
fibroblasts (CAFs). CAFs are important in regulation of 
EMT in tumor cells. CAFs are also important in the 
induction of stem cell characteristics. CAFs were 
determined to induce EMT and invasion through a 
monoamine oxidase A (MAOA)/mTOR/HIF-1alpha 
signaling pathway in prostate cancer cells. This pathway 
induced ROS which resulted in the migratory and 
aggressive characteristics of the prostate cancer cells. 
The CAFs also increased CXCR4 and IL-6R expression 
in the prostate cancer cells. CUR was shown to inhibit 
all these processes [191].  
  
The modified CUR EF24 has been shown to target the 
expression of miR-21 and NF-kappaB in DU145 
prostate cancer and B16 murine melanoma cells. EF24 
also increased the expression of various miR-21 target 
genes including PTEN and programmed cell death 4 
(PDCD4) a gene which inhibits neoplastic trans-
formation [192].  
 
CUR has been shown to inhibit prostate cancer growth. 
CUR induced the accumulation of cyclin-dependent 
kinase inhibitor 1A (CDKN1A = p21Cip-1) protein but 
not its mRNA in a dose-dependent fashion suggesting 
that CUR elicited effects at the post-transcriptional 
level, e.g., at the translational level. It was determined 
that miR-208 was specifically inhibited by CUR. 
Furthermore, miR-208 specifically bound the 
3’untranslated region (3’UTR) of CDKN1A mRNA. 
Overexpression of miR-208 in prostate cancer cells 
prevented the inhibitory effects that CUR has on 
proliferation [193].  
 
CUR can also induce the demethylation of the Neurog1 
gene which is involved in preventing growth of the 
LNCaP prostate cancer cell line [194]. CUR can also 
induce the demethylation of the nuclear factor 
erythroid-2 (NF-E2) related factor-2 (NRT2) gene 
which in turn activates (NQO1), heme oxygenase-1 
(HO1) and an antioxidant stress pathway which can 
prevent growth in mouse TRAMP-C1 prostate cancer 
cells [195].  
 
CUR can have potent effects on cancer associated 
fibroblasts (CAFs) which are important in prostate 
cancer progression. CAFs were shown to stimulate 
EMT and invasion in prostate cancer cells EMT. This 
was mediated  by  a monoamine  oxidase A (MAOA)/ 
mammalian target of rapamycin (mTOR)/HIF-1alpha 
signaling pathway. This pathway also involves ROS 
which induces the prostate cancer migration. CAFs 
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were determined to be responsible for the increase in 
CXC chemokine receptor 4 (CXCR4) and interleukin-6 
(IL-6) receptor. CUR treatment inhibited these 
pathways as well as the invasion and EMT of the 
prostate cancer cells that was normally induced by the 
CAFs [196].  
 
The effects of novel poly(lactic-co-glycolic acid)-CUR 
nanoparticles (PLGA-CUR NPs) on prostate cancer 
cells were determined. The PLGA-CUR NPs were 
determined to internalize in prostate cancer. Upon 
internalization, they release bioactive CUR into the cells 
and inhibited colony formation and tumor regression 
better than regularly delivered (free) CUR. The PLGA-
CUR NPs were determined to inhibit beta-catenin and 
AR expression in cells. PLGA-CUR NPs also 
suppressed Akt and STAT3 phosphorylation which 
resulted in the induction of apoptosis. Part of the 
suppression of apoptosis was determined to be by 
inhibition of MCL-1 and BCL-XL expression and 
induction of PARP cleavage. PLGA-CUR NPs also 
resulted in decreased miR-21 and increased miR-205 
expression [197].  
 
Effects of curcumin on hypoxia, HIF and ROS 
 
Hypoxia is important in many key events involved in 
cancer development including cell survival, tumor 
invasion, angiogenesis and metastasis. HIF over-
expression induced by hypoxia is linked with 
therapeutic-resistance. Hypoxia and HIF are important 
in EMT, CSCs and inflammation, all contributing 
factors for therapeutic resistance. In studies with 
pancreatic cancer cells, hypoxia and HIF have been 
shown to be important in the expression of IL-6, miR-
21, miR-210 and VEGF as well as the CSC-related 
factors: NANOG, OCT-4 and EZH2. The expression of 
these proteins can be inhibited by treatment with CDF 
under hypoxic conditions. These studies were further 
elucidated with an orthotopic pancreatic model and 
similar results were obtained [198].  
  
Other studies have shown that CUR and synthetic 
analogs can induce ROS and decrease SP factors by the 
induction of specific miRs in CRC cells. The effects of 
cyclohexanone and piperidine analogs of CUR were 
examined in this study. The IC50 ranged from 10 μM for 
Cur to 700 nM for the most active synthetic piperidine 
analog RL197. CUR and RL197 inhibited the 
expression of the SP transcription factors and genes 
they regulated such as EGFR, c-MET, survivin, BCL-2, 
Cyclin D1 and both p65 and p50 subunits of NF-
kappaB. This was determined to occur by CUR and 
RL197 inducing ROS. ROS induced the expression of 
ZBTB4 and ZBTB10 which inhibited the expression of 
the SP proteins and various miRs including: miR-27a, 
miR-20a, miR-17-5p which normally regulate ZBTB4 
and ZBTB10 [199].  
 
Effects of curcumin on WNT, NOTCH and HH 
signaling pathways 
 
CUR suppresses the release of cytokines such as: IL-1, 
IL-6 and IL-8 which can stimulate the generation of 
CSCs. In addition, CUR suppresses various signaling 
pathways including WNT, NOTCH, HH and FAK. 
While curcumin has effects against CSC, it had less 
toxicity against normal stem cells [200].  
 
Curcumin—problems with biological extracts 
 
Most sources of CUR are biological extracts and not 
homogenous preparations of CUR. Numerous other 
“nutraceuticals” may be present in these extracts which 
makes identification of a specific biological properties 
difficult to precise ascribe to CUR. Recently the ability 
of CUR to acts as panassay interference compounds 
(PAINS) and an invalid metabolic panaceas (IMPS) 
compound has been discussed. CUR has been reported 
to have poor pharmacokinetic (PK) and pharmoco-
dynamic properties (PD). CUR has been suggested to 
lack the properties required to be a good drug candidate 
[201].  
 
Clinical trials have so far not revealed that CUR is 
effective clinically although some of the problems with 
CUR may be due to the low solubility of CUR and its 
rapid turnover. This may have resulted from the 
methods used to deliver CUR to the patient as well as 
the duration of patient treatments. Furthermore, some of 
the patients selected for the clinical trial may have had 
advanced diseases which could preclude the evaluation 
of the effectiveness of treatment with a drug or natural 
products which may take years to elicit demonstrable 
biological effects in humans. However, the presence of 
the additional components in the CUR extract may 
provide certain health benefits which may be difficult to 
biochemically and medically evaluate. More effective 
means to deliver CUR to patients may be achieved by 
more novel delivery approaches such as nanoparticles. 
 
Effects of berberine, a plant derived compound 
which induces many effects 
 
BBR is an isoquinoline quaternary alkaloid (a 5,6-
dihydrodibenzo[a,g]quinolizinium derivative) which has 
been used in traditional Chinese and Indian medicine 
for centuries [202,203]. BBRs are derived from plants 
such as: Berberis aetnensis C. Presl., Berberis aristata, 
Berberis vulgaris, Coptis chinensis, Coptis japonica, 
Coptis rhizome, Hydrastis canadensis, Phellondendron 
amurense and Tinosora cordifolia. A diagram 
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illustrating some of the effects of BBR on various 
biological processes is present in Figure 10. BBR has 
even been isolated from plants that grow in the vicinity 
of Mt. Etna in Sicily [204].  
 
BBR, like CUR and RES, is a dietary supplement and 
can be purchased over the counter at many different 
types of stores. BBR has been used in treatment of 
patients with various conditions/diseases including: 
abdominal pain, coronary artery disease, diabetes, 
diarrhea, fatty liver disease, gastroenteritis, hyper-
lipidemia, hypertension, metabolic syndrome, neuro-
degeneration, obesity, polycystic ovary syndrome and 
may be used eventually to treat certain cancers. BBR 
has documented to have anti-diabetic, anti-
inflammatory and anti-microbial (both anti-bacterial 
and anti-fungal) properties. BBRs can inhibit IL-6, 
TNF-alpha, monocyte chemo-attractant protein 1 
(MCP1) and COX-2 production and expression. BBRs 
can also effect prostaglandin E2 (PGE2) and decrease 


































cluding: MMP2 and MMP9. Some of these effects may 
be mediated by the Raf/MEK/ERK and NF-kappaB 
pathways [205,206].  
 
Effects of berberine on DNA structure and 
replication 
 
BBR induces double strand DNA breaks and has similar 
effects as ionizing radiation [207]. In some cell types, 
this response has been reported to be TP53-dependent 
[208]. 
 
BBR has multiple intracellular targets such as nucleic 
acids and proteins involved in the regulation of cell 
growth including: DNA topoisomerase, estrogen 
receptors, NF-kappaB, TP53 and telomerase [209-213].  
 
Some of the interactions of BBR and DNA and RNA 
may be due to the nitrogen atom at the 7-positon in the 
alkaloid BBR skeleton. This positively-charged nitrogen 





































pathways which may  result  in  suppression  of  cell  growth,  induction  of  apoptosis,  autophagy,  senescence, DNA  double
strand  breaks  or  inhibition  of  cell  cycle  progression  and DNA  replication.  These  events  are  indicated  by  red  arrows.  In
addition, BBR treatment can result in the suppression of many important proteins leading to decreased growth, decreased
DNA synthesis, mitochondrial membrane potential, cell cycle arrest and inflammation indicated in black closed arrows. 
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BBR and nucleic acids and induce telomerase inhibition 
and topoisomerase poisoning [214,215]. BBR have been 
shown to suppress BCL-2 and expression of other genes 
by interacting with the TATA-binding protein and the 
TATA-box in certain gene promoter regions 
[216,217].  
 
Effects of berberine on induction of apoptosis, 
autophagy, cell cycle arrest and invasion 
 
BBR has been demonstrated to have effects on the 
expression proteins involved in apoptosis, autophagy, 
cell cycle progression and invasion including: BCL-2, 
BCL-XL, PARP1, Beclin-1, TP53, p21Cip1, MMP9 and 
others [218]. Combined treatment with BBR and 
inhibitors of the Raf/MEK/ERK and PI3K/Akt 
pathways led to suppression of MMP-9 expression and 
invasion [219,220]. 
  
Effects of berberine on mitochondria and 
suppression of gero-conversion 
 
BBR has been shown in some studies to localize to the 
mitochondria and inhibit the electron transport chain 
and activate AMPK. The effect of BBR on the 
premature stress-induced senescence that is induced by 
the chemotherapeutic drug mitoxantrone has been 
examined. BBR was determined to inhibit senescence 
by analysis of senescence-associated beta galactosidase, 
p21Cip1 induction, gamma H2AX expression and levels 
of ribosomal S6 protein phosphorylation. BBR was 
determined to alter gero-conversion from the process of 
cell cycle arrest to the induction of senescence. This 
was determined to be due to targeting the activity of 
mTOR/S6 and the generation of ROS [221,222].  
 
BBR has been shown to decrease mitochondrial 
membrane potential and intracellular ATP levels. BBR 
induces AMPK activation and inhibits mTORC1 
phosphorylation by suppressing phosphorylation of S6K 
at Thr 389 and S6 at Ser 240/244. BBR also suppresses 
ERK activation in MIA-PaCa-2 cells in response to fetal 
bovine serum, insulin or neurotensin stimulation. 
Activation of AMPK is associated with inhibition of the 
PI3K/PTEN/Akt/mTORC1 and Raf/MEK/ERK path-
ways which are associated with cellular proliferation. 
The effects of low doses of BBR (300 nM) on MIA-
PaCa-2 cells were determined to be dependent on 
AMPK as knockdown of the alpha1 and alpha2 catalytic 
subunits of AMPK prevented the inhibitory effects of 
BBR on mTORC1 and ERK activities and DNA 
synthesis. In contrast, higher doses of BBR inhibited 
mTORC1 and ERK activities and DNA synthesis by 
AMPK-independent mechanisms [223,224].  
 
Effects of berberine on cancer and cancer associated 
pathways 
 
BBR has been shown to have minimal effects on 
“normal cells” but has anti-proliferative effects on 
cancer cells (e.g., breast, liver, CRC cells) [225-227]. 
BBR induces G1 phase arrest in pancreatic cancer cells, 
while other drugs such as gemcitabine induce S-phase 
arrest [228].   
 
Berberine effects on bladder cancer 
 
BBR was determined to enhance the effects of 
epirubicin (EPI) on T24 bladder cancer cells. EPI 
induced cell cycle arrest at G0/G1 and proteins 
associated with apoptosis and cell cycle arrest such as 
caspase 9 and cleaved caspase 3, BAX, TP53 and 
p21Cip-1. Co-treatment with BBR treatment resulted in 
enhanced levels of many of these proteins associated 
with apoptosis, increased ROS levels and decreased 
levels of BCL-2 [229].  
 
Berberine effects on brain cancer 
 
BBR induces some of its anticancer effects by inducing 
apoptosis, autophagy, cell cycle arrest and cellular 
senescence. In some glioblastoma cells, BBR has been 
shown to inhibit EGFR signaling by suppression of the 
Raf/MEK/ERK pathway but not AKT signaling [230].  
 
BBR can also induce autophagy in GBM. BBR targets 
the AMPK/mTOR/ULK1 pathway. This leads to 
autophagy flux which is accompanied by impaired 
glycolytic capacity. This results in reduced proliferative 
and invasive properties as well as increased apoptosis 
[231].  
  
BBR has been shown to induce G1 arrest and apoptosis 
in glioblastoma cells by the mitochondrial/caspase 
pathway. The IC50 for BBR was determined to be 134 
micrograms/ml. Increased p27Kip1 and decreased CDK2, 
CDK4, Cyclin D and Cyclin E were observed. Increased 
BAX/BCL2 ratio was observed. The mitochondrial 
membrane potential was disrupted and activated caspase 
3 and caspases 9 were observed [232]. BBR can also 
inhibit arylamine N-acetyltransferase and DNA adduct 
formation in glioblastoma cells [233].  
 
Berberine effects on breast cancer 
 
BBR can bind to the vasodilator stimulated protein 
(VASP). VASP is overexpressed in breast cancer cells 
with high mobility and inhibits actin polymerization. 
BBR binds VASP in MDA-MB-231 cells and 
suppressed proliferation and tumor growth [234].  
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BBR can also suppress the proliferation and migration 
of certain breast cancer cells by altering the activity of 
ephrin-B2 signaling. BBR treatment decreased VEGFR, 
Akt and ERK1,2 activation and the expression of 
MMP2 and MMP9 [235].  
  
BBR was determined to suppress canine mammary 
gland tumors in vitro. These studied used BBR 
concentration ranging from 10-200 micromolar. 
Treatment with 10-200 micromolar BBR inhibited 
proliferation [236].  
  
BBR has been shown to increase the anti-tumor effects 
of tamoxifen (TAM) in both drug-sensitive MCF-7 and 
drug-resistant MCF-7/TAM cells. The combined 
treatment of BBR and TAM resulted in enhance 
cytotoxic activity, G1 arrest and apoptosis potentially 
due to p21Cip-1 induction and increased BAX/BCL2 ratio 
[237].  
  
The combination of BBR and CUR has been shown to 
be effective in suppressing the growth of certain breast 
cancer cell lines. The combined treatment was more 
effective than treatment with either BBR or CUR by 
themselves. The combined treatment resulted in 
phosphorylation of JNK and Beclin1 and decreased 
phosphorylation of BCL-2 [238].  
  
BBR induced apoptosis by increased ROS in certain 
breast cancer cells (MCF-7 and MDA-MBA-231). JNK 
was activated by the treatment and triggered 
mitochondrial membrane depolarization. BAX was 
increased while anti-apoptotic family members such as 
BCL-2 were decreased [239].  
 
BBR and tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) have synergistic effects on 
inducing apoptosis in TNBC. p38MAPK was activated in 
response to the combined treatment. Suppression of 
p38MAPK enhanced BBR/TRAIL induced apoptosis [240].  
 
The combination of BBR and cisplatin suppressed 
breast cancer growth by inducing DNA breaks and 
caspase 3-dependent apoptosis in breast cancer cells. 
Combining BBR and cisplatin resulted in potentiating 
the effects and BBR sensitized the cells to cisplatin. 
BBR increased the extent of DNA damage and 
apoptosis normally induced by cisplatin [241].  
  
BBR decreased breast cancer cell migration and 
chemokine expression. This was determined by wound 
healing assays and RNA analysis of chemokine 
receptors in MCF-7 breast cancer cells [242].  
  
Cotreatment of certain breast cancer cell lines with BBR 
and doxorubicin increased cytoxicity and apoptosis. 
BBR induced G2/M phase arrest in T47D but in G0/G1 
in MCF-7 cells. The IC50 for BBR was determined to be 
approximately 25 micromolar after 48 hours of 
treatment for both cell lines [243].  
  
BBR was determined to increase the activities of 
numerous proteins involved in proliferation including: 
JAK2, PI3K, AP-1 and NF-kappaB. These events lead 
to decreased IL-8 expression in the TNBC cell line 
MDA-MB-231. The IL-8 stimulated invasion and was 
suppressed by BBR. BBR also decreased MMP2, 
MMP9, E-cadherin, EGF, bFGF, and fibronectin in the 
breast cancer cells. The effect of BBR were inhibited by 
JNK and p38MAPK inhibitors but increased by 
p38MAPK activators [244].  
 
Berberine effects on chemical carcinogen-induced 
cancers 
 
BBR suppressed chemical carcinogen-induced tumors 
in mice and rats [245]. BBR (at high doses, 40 mg/kg) 
has been shown to suppress CRC in a chemical 
carcinogenesis model in mice. This inhibition was 
shown, in this study, to be through TOR inhibition and 
NF-kappaB activation [246].  
 
Berberine effects on cervical cancers 
 
BBR increased TP53 mRNA transcripts in HeLa229 
cells. In contrast BBR decreased BCL-2 and COX2 
mRNA transcripts [247]. BBR has also been shown to 
have effects on HPV-18 E6-E7 oncoproteins by the 
targeting of TP53 in HeLa cells. This occurred by 
reprogramming of epigenetic modifications and altering 
the microtuble network. These studies suggest that BBR 
may be a promising agent for treatment of cervical 
cancer [248].  
 
Berberine effects on chondrosarcoma 
 
BBR induced cell cycle arrest at G2/M in the HTB-94 
chondrosarcoma cell line by increasing TP53 and 
p21Cip1 expression and decreasing cyclin B1, CDC2, 
CDC25c and pRB expression. BBR stimulated 
phosphorylation of both Akt and p38MAPK.  Suppression 
of Akt and p38MAPK signaling decreased the effects that 
BBR had on TP53 and p21Cip1 mediated cell cycle arrest 
and resulted in proliferation [249]. 
 
Berberine effects on CRC 
 
BBR inhibited intestinal polyps growth in the min/+ 
mouse model. This was shown to be due to regulation 
of macrophage polarity. Decreases in F4/80, mannose 
receptor (MR) and COX2 in the stroma and increases in 
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iNOS occurred. BBR was shown to decrease the 
migration and invasion of the cells [250].  
  
BBR suppressed the expression of E-cadherin and 
partitioning defective 3 (Par-3) in CRC. miR-429 was 
determined to be upregulated in CRC in comparison to 
normal tissues suggesting that miR-429 can function as 
an oncomir. Upon treatment with BBR and evodiamine 
(EVO) the levels of miR-429 in the tumor cells 
decreased [251]. A diagram depicting some of the 
effects of BBR on miRs. TP53 and regulation of cancer 
growth is presented in Figure 11.  
  
BBR has been shown to synergize with the HSP-90 
inhibitor NVP-AUY922 in inducing death of human 








































upregulation of survivin expression which can 
contribute to drug resistance. In contrast, when BBR 
was combined with NVP-AUY922, the growth of the 
normally resistant cells was reduced which was 
mediated by miR-296-5p-mediated suppression of the 
Pin1/beta-catenin/cyclinD1 signaling pathway and 
inhibition of CDK4 expression [252].   
  
BBR inhibits COX2 and PEG2 in CRC. This results in 
decreased phosphorylation of JAK2 and STAT3 as well 
as MMP2 and MMP9 expression. BBR prevented the 
invasion and metastasis of CRC cells via inhibiting the 
COX2/PGE2 and JAK2/STAT3 signaling pathways. 
The JAK2 inhibitor AZD1480 blocked the effects of 
COX2/PGE2 on MMP2 and MMP9 expression. Thus, 
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hibiting the COX2/PGE2 and JAK2/STAT3 signaling 
pathways [253].  
 
Berberine effects on endometrial cancer 
 
BBR and MET will induce the lipolysis-stimulated 
lipoprotein receptor (LSR), which is a component of 
tricellular tight junctions in endometrial cancer cells. 
BBR and MET suppressed cell migration and invasion. 
This occurred by BBR and MET counteracting the 
effects of leptin on LSF expression [254].  
 
Berberine effects on esophageal cancer 
 
Galangin is present in Alphina officinarum Hance and 
propolis (bee glue, a sealing mixture produced by honey 
bees). It has both anti-cancer and anti-oxidative 
properties. Combining galangin with BBR has been 
shown to have synergistic effects on inhibiting the 
growth of CRC. This combination resulted in increased 
ROS levels in esophageal cells. In contrast, treatment 
with either galangin or BBR by themselves suppressed 
WNT/beta-catenin signaling, the combination increased 
the suppression. The effects of these combination were 
also observed in in vitro and  in vivo experiments  [255].  
BBR has been observed to inhibit the expression of the 
chemokine receptors (CXCR4 and CCR7) at the 
mRNA level in esophageal cancer cells. BBR 
suppressed the migration of KYSE-30 esophageal 
cancer cells [256].  
 
Berberine effects on gastric cancer 
 
BBR has been shown to increase the activity of the 
EGFR inhibitors cetuximab and erlotinib against gastric 
cancer in vitro and in vivo [257]. The effects of BBR 
can be increased upon combination with d-limonene in 
gastric cancer cells. The combination of these two 
agents resulted in enhanced ROS production and 
apoptosis induction via the mitochondria-mediated 
intrinsic pathway and cell cycle arrest [258].  
  
BBR has been shown to result in reduced IL-8 secretion 
in gastric cancer cells. This lead to decreased p38MAPK, 
ERK1,2 and JNK activities [259]. BBR treatment has 
been shown to reverse cisplatin-resistance and induce 
caspase-dependent apoptosis in two cisplatin-resistant 
gastric cancer cell lines. BBR induced miR-203 
expression. Experimentally-induced miR-203 expres-
sion resulted in cisplatin-sensitivity. miR-203 bound the 
3-UTR of BCL-W [260].  
  
STAT3 and survivin signaling has been shown to be 
involved in chemotherapeutic drug resistance of gastric 
cancer. BBR and CUR will synergize with 5FU and 
target STAT-3 which can lead to sensitivity to 5FU in 
gastric cancer cells. However, in these studies, does of 
29 micromolar were required for IC50 values [261].   
 
Berberine effects on HCC 
 
BBR can stimulate G2/M cell cycle arrest in HCC and 
other cells. Hepatic nuclear factor 4 alpha (HNF4alpha), 
a key liver transcription factor, can transactivate the 
Exo 70 promoter region. BBR-mediated cell cycle arrest 
was determined to occur by down regulation of 
HNF4alpha and Exo-70 [262]. BBR has been shown to 
induce pyroptosis in HCC. Pyroptosis is a caspase-1 
dependent programmed cell death program [263].  
  
BBR can induce apoptosis and autophagic cell death in 
HEP-G2 HCC cells. Induction of apoptosis and 
autophagy were shown to require AMPK. This resulted 
in elevated expression of inactive acetyl-CoA carbo-
xylase (ACC). Suppression of AMPK by RNAi or by 
the AMPK inhibitor (compound C) suppressed the 
effects of BBR. In contrast, the AMPK activator 
AICAR stimulated cytotoxic effects. BBR was shown to 
inhibit mTORC1 activation by stimulating AMPK 
[264].  
 
miR-22-3p has been determined to be detected at 
decreased levels in HCC. BBR will increase miR-22-3p 
in HCC. In these studies, high doses of BBR (100 
micromolar) inhibited cell growth at 24 hr. time 
interval. BBR treatment decreased the expression of 
SP1, cyclin D1 and BCL2. BBR induced miR-22-3p 
which bound SP1 and suppressed cyclinD1 and BCL2 
[265].  
  
BBR has also been shown to decrease cyclinD1 
expression by inducing its proteasomal degradation in 
HEPG2 cells. BBR stimulates the Thr 286 
phosphorylation of cyclin D1 which stimulates its 
nuclear export to the cytoplasm for proteasomal 
degradation. BBR also induced the component of the 
proteasome required for cyclin D1 proteasomal 
degradation, namely SKP, cullin and F-box containing 
complex-beta-transducin repeat containg protein 
(SCFbeta-TrCP) [266].  
  
BBR has also been shown to induce plasminogen 
activator inhibitor-1 (PAI-1) and suppress uPA in HCC 
cells which suppressed their invasiveness and motility. 
BBR also induced COX2, NF-kappaB and MMP9 down 
regulation and inactivated MAPK and ERK1,2. The 
effects of BBR on uPA were attributed to the activation 
of PAI-1 [267].  
  
BBR activates TP53 which increases the expression of 
miR-23a in HCC. BBR induced TP53 which in turn 
stimulated p21Cip1 and GADD45alpha expression. 
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Suppression of miR-23a blocked binding of TP53 to the 
chromatin and blocked transcriptional activation of 
p21Cip1 and GADD45alpha. BBR induced miR-23a may 
suppress never in mitosis A (NIMA) kinase 6 (NEK6) 
and result in block of cell cycle in G2/M [268]. NEK6 
may have effects on TP53. NEK6 has been shown to 
antagonize TP53 induced senescence [269]. By using 
RNA-Seq analysis, BBR has been shown to modify the 
expression of genes in the TP53 and cell cycle pathways 
[270].  
  
BBR has been shown to increase the effectiveness of 
rapamycin in inducing the cell death of human 
hepatoma cells. The combination of BBR and 
rapamycin resulted in decreased levels of Thr 389-
phosphorylated p70S6K compared to individual 
treatment [271].  
  
The effects of BBR on the arachidonic acid (AA) 
metabolic pathway in HCC has been examined. BBR 
altered the viability and apoptosis of HCC cells in a 
dose-dependent fashion by inducing the translocation of 
apoptosis-inducing factor between the mitochondria and 
nucleus. BBR suppressed the levels of cytosolic 
phospholipase A2 (cPLA) and COX2 which increase 
the ratio of AA to PEG2 [272].  
 
Berberine effects on leukemia 
 
BBR prepared from a Berberis libanotica (BI) extract 
was demonstrated to target NF-kappaB, COX2 and 
PI3K/Akt signaling to induce apoptosis by a 
mitochondrial/caspase dependent pathway in erythro-
leukemia cell lines [273].  
 
Berberine effects on lung cancer 
 
The effects of combination of BBR with MEL have 
been examined in lung cancer cells. MEL was shown to 
enhance the effects of BBR on suppression of cell 
growth, colony formation and cell migration. MEL was 
demonstrated to promote cleavage of caspase 9 and 
PARP. MEL increased the effect of BBR on sup-
pression of BCL-2 and increased apoptosis in part by 
stimulating the release of cytochrome C. MEL also 
promoted the effect of BBR on other biochemical 
events involved in cellular proliferation [274].  
  
BBR has been shown to suppress STAT3 activity in 
human lung cancer cells. BBR inhibited doxorubicin-
mediated STAT3 activation which was associated with 
sensitivity to doxorubicin treatment. BBR also sup-
pressed the sphere forming capacity of these cells 
[275].  
 
Berberine effects on multiple myeloma 
 
BBR has been shown to induce TP53 expression by 
suppressing the DNMT1 and DNMT3B DNA 
methyltransferases in MM which will result in TP53 
gene expression as the methylation status of the TP53 
promoter region changes [276]. This can alter TP53-
mediated gene expression which includes many genes 
involved in regulation of the cell cycle as well as miRs 
including miR-21 which normally functions as an 
oncomir and can regulate the expression of PDCD4. 
miR-21 normally suppresses PDCD4. In the presence of 
BBR, miR-21 is suppressed. miR-21 is regulated by IL-
6/STAT3 signaling which is also suppressed by BBR in 
MM cells [277].   
  
BBR may affect multiple miRs in MM cells. The miR-
99a~125b cluster was studied with t-anti-mirs 
(Antagomir) that have complete complementary 
antisense locked nucleic acids (LNAs) directed against 
mature miR-125b (anti-miR-125b). BBR was 
determined to suppress miR-99~125b, miR-17~92 and 
miR-106~25 in MM cells. The TP53, ERB and MAPK 
pathways were linked with the three miR clusters. In 
these studies, BBR suppressed the three miR clusters 
and downstream TP53, ERB and MAPK signaling 
pathways [278].  
 
Berberine effects on melanoma 
 
BBR isolated from Coptidis rhizome, has been shown to 
inhibit the migration, EMT and invasion of melanoma 
cells. BBR suppressed PI3K/Akt and retinoic acid 
receptor (RAR) alpha signaling. In contrast, RARbeta 
and RARgamma signaling were upregulated. BBR 
treatment may reverse EMT in melanoma cells [279].   
 
Berberine effects on neuroblastoma 
 
BBR has been shown to inhibit stemness, EMT and 
induce neuronal differentiation in neuroblastoma cells. 
BBR inhibited the expression of many genes associated 
with neuronal differentiation including: microtubule-
associated protein 2 (MAP2), beta-III tubulin and neural 
cell adhesion molecule (NCAM) which resulted in 
neurons that were viable. In contrast, BBR also 
suppressed the expression of many genes associated 
with cancer stemness such as beta-catenin, CD133, 
NESTIN, N-MYC, NOTCH and SOX2. BBR induced 
cell cycle arrest at G0/G1 and suppressed proliferation 
which resulted in increased BAX/BCL2 ratio. BBR was 
shown to regulate EMT in part by downregulating the 
PI3K/Akt and RAF/MEK/ERK pathways and 
upregulating the p38MAPK pathway [280].  
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Berberine effects on oral cancer 
 
BBR has been shown to have anti-cancer effects on KB 
oral cancer cells but not on the cell viability of normal 
primary human oral cells. BBR induced many markers 
associated with apoptosis such as DNA fragmentation, 
nuclear condensation and caspases 3 and 7. BBR 
induced the expression of FAS-L which resulted in 
activation of caspase 8, 9, 3 and PARP. In contrast, 
BBR treatment resulted in decreased BCL2 and BCL-
XL expression. Induction of FASL by BBR was 
determined to be dependent on p38MAPK which resulted 
in decreased MMP2 and MMP9 expression [281].  
 
Berberine effects on osteosarcoma 
 
BBR has been shown to suppress proliferation and 
induce DNA damage in osteosarcoma MG-63 cells 
[282]. BBR was also shown to inhibit proliferation, 
induce apoptosis and suppress PI3K/Akt signaling in 
U20S human osteosarcoma cells. BBR treatment 
resulted in increased BAX and PARP expression and 
decreased BCL2 expression [283].  
 
Berberine effects on ovarian cancer 
 
BBR suppressed proliferation of SKOV3 ovarian cancer 
cells. BBR decreased the expression of BCL-2 and 
survivin while increasing the expression of BAX. BBR 
was demonstrated to synergize with cisplatin in 
inducing death of SKOV3 cells. BBR treatment resulted 
in restoration of the demethylation status of MutL 
homolog 1, colon cancer, nonpolyposis type 2 (hMLH1) 
promoter region and increased its expression. hMLH1 
encodes a protein involved in DNA mismatch repair 
[284].  
  
BBR has been shown to augment the effects of cisplatin 
in inducing cell cycle arrest in A2780 ovarian 
carcinoma cells. BBR inhibited miR-93 expression and 
increase the expression of the PTEN tumor suppressor 
which is a target of miR-93. miR-93 levels were higher 
in cisplatin resistant A2780 cells [285].  
 
Berberine effects on pancreatic cancer 
 
In MIA-PaCa-2 cells, the KRAS gene is mutated and 
results in the activation of the PI3K/PTEN/Akt/mTORC1 
and Raf/MEK/ERK pathways. Both pathways are 
usually associate with proliferation. MIA-PaCa-2 cells 
also lack WT TP53, which can have effects on cell 
cycle progression, proliferation, cellular senescence and 
tumorigenicity. BBR treatment was determined to 
inhibit DNA synthesis and proliferation of the 
pancreatic cancer cells. So, in these studies, the growth 
inhibitory effects of BBR were independent of WT 
TP53. MET was determined to induce similar effects in 
the pancreatic cancer cells. In addition, tumor xenograft 
experiments were performed. MIA-PaCa-2 cells were 
implanted into the right flanks of nu/nu mice. When the 
tumors reached a mean diameter of 2 mm, the animal 
were treated with BBR (5 mg/Kg), MET (250 mg/Kg) 
or vehicle control. The drugs were administered once 
daily intraperitoneally (50 microliters/mouse). This 
protocol resulted in a decrease in the size of the 
xenografted tumors by 70% at the end of the 
experimental protocol (day 29). MET treatment also 
reduced tumor volumes by similar amounts. In this 
study, BBR inhibited DNA synthesis, cell cycle 
progression, proliferation in vitro and tumor growth in 
mice. BBR was also observed to be well tolerated and 
did not affect the weight of the mice [223,224].  
  
BBR has been shown to suppress genes associated with 
stemness such as SOX2, POU5F1, NANOG and 
NOTCH in the side population of certain pancreatic 
cancer cell line PANC-1. The side population fraction is 
frequently associated with CSCs [286].  
 
Berberine effects on prostate cancer 
 
In certain prostate cancer cell lines, BBR induced ROS 
production which resulted in TP53 translocation to the 
mitochondria. When TP53 was present in the 
mitochondria, it interacted with cyclophilin D (Cyp D) 
which resulted in the opening of the mitochondrial 
permeability transporter (mPTP) [287].  
  
BBR has been shown to decrease 22Rv-1 prostate 
cancer growth and cellular testosterone formation. 
These studies have indicated that BBR may be 
appropriate as a skeleton backbone for the design of 
aldo-keto-reductase family member inhibitors 
(AKR1C3) [288].  
  
BBR treatment results in suppression of migration and 
invasion of prostate cell cells. BBR treatment resulted 
in decreased expression of certain mesenchymal genes 
such as: bone morphogenetic protein 7 (BMP7), nodal 
growth differentiation factor (NODAL) and SNAIL. 
The expression of these genes is normally associated 
with shorter survival of prostate cancer patients [289].  
  
BBR inhibited HIF-1alpha and VEGF expression in 
prostate cancer cells and increased their radio-
sensitivity in in vitro as well as in animal studies 
[290].  
  
BBR can target EGFR signaling to suppress the 
proliferation of prostate cancer cells in vitro. BBR was 
shown to accumulate inside the cells that were in G1 
phase and increased the induction of apoptosis. BBR 
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suppressed both prostate specific antigen expression and 
EGFR activation after EGF treatment [291].  
 
Berberine effects on skin squamous cell carcinoma 
 
BBR has been shown to inhibit the proliferation of 
squamous skin cell carcinoma cells. BBR was demons-
trated to induce apoptosis and inhibit migration of the 
skin cancer cells [292].  
 
Berberine effects on thyroid carcinoma 
 
BBR has been shown to inhibit the activity of the RET 
tyrosine in medullary thyroid carcinomas (MTC). This 
occurred by stabilization of G-quadruplex structures 
present on the RET promoter region in the MTC TT cell 
line. In contrast, minimal effects were observed on the 
papillary thyroid TPC1 cell line. The TPC1 cell line has 
a chromosomal rearrangement and they lack the G-
quadruplex forming region in the RET promoter region 
[293].   
 
Berberine effects on uterine leiomyoma 
 
BBR inhibited proliferation of human uterine 
leiomyoma (UtLM). The expression of cyclin A1, 
cyclin B, and Cdk1 were decreased upon BBR 
treatment, while the expression of Cdk4, p21Cip1 and 
TP53 were increased. BBR induced upregulation of 
BAX and Annexin V staining. In contrast, BBR did not 
appear to affect cell proliferation in “normal” human 
uterine smooth muscle (UtSMC) cells [294].  
 
Berberine effects on TP53 signaling 
 
Activation of the TP53 pathway has been reported after 
BBR treatment. However, we and others have 
demonstrated that BBR and modified derivatives can 
exert effects in cells containing mutant TP53. Some 
authors have claimed that the effects of BBR in some 
cancer cells are TP53-dependent. The effects of BBRs 
on neuroblastoma cells have been postulated to be 
TP53-dependent [295]. However, the concentrations of 
BBR used in these studies were often very high from 25 
to 100 micromolar and often the concentrations of 
glucose were high (25 mM). The effects of BBR and 
MET on pancreatic cancer cells have been determined 
to be affected by glucose concentrations as low glucose 
concentrations (3 mM) result in AMPK-dependent 
effects while high glucose concentration result in 
AMPK-independent effects. Some studies have also 
been performed with prostate and lung cancer cells. 
However, in some of these studies, different cell lines 
were used as well as culture conditions to make these 
conclusions and the cells may have additional mutations 
besides TP53 which make them sensitive or resistant to 
BBRs. The IC50s for BBRs were over 50 micromolar. 
These studies examined the effects of BBR on prostate 
and lung cancer tumors in mice respectively [296,297].  
 
Effects of berberine on bacteria 
 
BBR has been shown to have anti-bacterial effects by 
increased ATP-induced inflammasome activation. BBR 
treatment resulted in macrophages releasing more 
caspase-1 p10 and IL-1beta. Suppression of AMPK 
prevented these effects. BBR also stimulated macro-
phages to kill engulfed bacteria and increased the 
survival of mice injected with certain bacteria [298].  
 
BBR has been shown to inhibit Fusobacterium 
nucleatum and associated opportunistic pathogens 
during CRC progression. BBR is believed to modulate 
the colonic tumor microenvironment [299].  
  
BBR and other components of essential oils 
(cinnamaldehyde eugenol and thymol), have been 
shown to have some effects when combined with 
streptomycin on food-borne bacteria such as Listeria 




Some derivatives of BBR have been made by cyclizing 
BBR. A35 targets topisomerase 1 (TOP1) and 
TOP2alpha. A35 can intercalate DNA and promote 
top2alpha cleavage complex formation. Thus, A35 is a 
topoisomerase poison. Studies with mice indicated that 
no cardiotoxicity was observed at least at the A35 
concentrations examined [301].  
  
The BBR-8 compound (Ber8) is a 9-substituted BBR. 
Ber8 has been shown to induce cell growth arrest and 
senescence in cancer cells. Ber8 induced DNA damage 
at the telomeric regions of the chromosome. Ber8 
stabilized G-quadraplexes at the telomere. Ber8 
stimulated the telomeric repeat factor 1 (TRF1) and 
protection of telomeres 1 (POT1) proteins and displaced 
them from the telomeres. This resulted in telomere 
uncapping [302].  
  
Novel phenyl-substituted BBRs have been created by 
copper-catalyzed azide-alkyne cyclo addition (click 
chemistry). Some of the compounds exhibited activity 
against MCF-7 breast cancer cells, SW-1990 pancreatic 
cancer cells and SMMC-7721 liver cancer cells. In 
contrast, less effects were observed with noncancerous 
human umbilical vein endothelial cell (HUVEC) cell 
lines [303,304].  
 
Other BBR derivatives have been synthesized. BBR 
compounds containing a single and four phenolic 
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groups exhibited increased up-regulation of superoxide 
dismutase (SOD) gene expression. The effects of the 
compounds were examined on human fibrosarcoma 
cells (HT1080). Some of the modified BBRs were 
determined to have enhanced activities [305].  
 
BBR dimers have been synthesized which display high 
affinity in binding G-quadruplexes [306].   
 
A panel of modified BBRs has been developed by 
Naxospharma in Milan, Italy [307,308]. The structures 
of the modified BBRs are presented in Figure 12. A key 











































aromatic moieties which have been added to the 13-
position of BBR alkaloid skeleton. This was achieved 
by addition of a hydrocarbon linker of variable length 
and functionality. These modifications were made to 
generate modified BBRs that may have a geometric 
propensity for additional stacking-type, noncovalent 
interactions that might interact with their intracellular 
targets in a more effective fashion resulting in enhanced 
biological and anti-cancer effects [309-314].  
 
The synthesis of these compounds has been described. 
The purity of  this  compound  has  been  ascertained by  
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lent Eclipse XDB-C18 (4.6 mm3 150 mm3 3.5 mm) 
column with a flow rate of the mobile phase (50% 
water, 50% acetonitrile plus 0.1% trifluoroacetic acid) 
that was maintained at 1.0 mL per minute. Absorbance 
was measured at 235, 265, 340, and 420 nm. The 
modified BBR NAX014 was less toxic than the non-
modified BBR as 30.9 mg/kg and 10.9 mg/kg were 
required for  the lethal dose (LD50s)  respectively  [312]. 
When the spacer between the 13 position of the BBR 
backbone and the added phenyl ring(s) was longer than 
3 C-atoms in length, increased cytotoxicity was 
observed. The LD50 for mice treated with BBR and 
some modified BBRs has been examined. BBR and 
modified BBRs induced apoptosis and cellular 
senescence and reduced microvesicle density in a 
HER2-overexpressing transgenic mouse model. The 
modified BBR NAX014, in this study, has been 
demonstrated to suppress (delay) tumor formation better 
than unmodified BBR at a “safe-dose” of 2.5 mg/kg 
twice a week. NAX14 induced growth inhibition and 
tumor vascularization through its anti-angiogenic effect. 
Some modified BBRs have been reported to be active 




BBR has been encapsulated in liposomes. This has been 
performed due to the poor aqueous solubility and rapid 
metabolism and to improve gastrointestinal absorption. 
The effects of BBR in nanoparticles have been 
examined in some cancer cell lines such as MCF-7, 
HepG2 and A549 [315].  
   
BBR solid lipid nanoparticles (SLN) were observed to 
improve bioavailability. BBR-SLNs were determined to 
suppress weigh gain, fasting blood glucose levels and to 
improve insulin tolerance in db/db diabetic mice. They 
also improved lipid function [316].  
 
The effects of BBR in nanoparticles have also been 
examined on hepatosteatosis. The effects of BBR SLN 
in nanoparticles on lipid metabolism in the liver were 
examined in db/db diabetic mice. The BBR SLNs 
inhibited body and liver weight gain. Serum alanine 
transaminase and liver triglycerides were also reduced 
in the mice. The highest levels of the drug were present 
in the liver. The BBR SLNs reduced the levels of fat 
accumulation. BBR SLNs also decrease the expression 
of key lipogenic genes. These results suggest that BBR 
SLNs may be eventually used for treatment of 
hepatosteatosis [317].  
  
Specialized BBR ferrous magnetic mesosporous Janus 
nanoparticle, (Fe3O4-mSiO2 NPs) have been developed 
to target liver cancers. These specialized NPs have a 
pH-sensitive group on the surface of the mesoporus 
SiO2 to creat tumor microenvironmental nanoparticles 
that display sensitivity for HCC cells [318].  
 
A phospholipid complex consisting of berberine in 
cucurbitacin B modified was made to try to increase the 
bile duct targeting deliver to cholangiocarcinoma (CC) 
[319].  
  
BBR liposomes have been synthesized to treat certain 
drug-resistant breast cancer including CSCs. The BBR 
liposomes were demonstrated to cross the CSC 
membrane and inhibit drug transporters including 
Abcc1, ABCC2, ABCC3 and ABCG2. The BBR lipo-
somes accumulated in the mitochondria and resulted in 
the activation of BAX and inhibition of inhibition of 
BCL2. This resulted in the induction of apoptosis 
[320].  
 
Compounds derived from similar plant sources 
 
Berberis libanotica Ehrenb (BLE) is a plant rich in 
alkaloids. Treatment of the prostate cancer cell lines 
(DU145, PC3 and Rv22-1) with BLE inhibited their 
growth and induced cell cycle arrest in G0/G1. BLE also 
suppressed spheroid forming capacity [321]. The related 
drug Berbamine, which is sometimes derived from the 
same plants, inhibits HCC tumor growth in tumor 
transplant studies [322].  
 
Effects of activators of AMPK on cancer 
 
AMPK is a critical kinase involved in monitoring the 
energy status in cells. Hence it plays critical roles in cell 
growth, cell cycle progression, protein synthesis, 
survival and tumorigenesis. AMPK has been shown to 
have effects on CSCs. The anti-diabetes drug MET is 
known to activate AMPK. Related drugs of the 
biguanide class of antidiabetic drugs which lower blood 
sugar levels were initially discovered in plants (French 
lilac or goat's rue Galega officinalis). There are 
approximately 272 clinical trials examining the effects 
of MET and cancer. In addition, natural compounds in 
our diet such as: capsaicin (present in chili peppers), 
genistein (present in soybeans and other plants), 
epigallocatechin gallate (EGCG, present in green tea) 
and quercetin (present in many fruits, berries and 
vegetables and especially in capers) will also activate 
AMPK. There are approximately 8 and 13 clinical trials 
examining the effects of capsaicin or quercetin on 
cancer respectively. Novel EGCG analogs have been 
recently determined to active AMPK more efficiently 
than MET. These compounds were examined on breast 
cancer cells with stem like properties. The novel EGCG 
compounds induced p21Cip1 and decreased activity of 
the PI3K/PTEN/Akt/mTORC1 pathway in the breast 
cancer cells with stem like properties [323].   
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Interestingly, BBR and MET may have some similar 
properties and both have been used to treat type II 
diabetes in traditional medicine (BBR) and in clinically 
(MET). MET treatment decreased in blood glucose 
levels by reducing hepatic gluconeogenesis and 
elevating glucose uptake. MET activates AMPK which 
suppresses mTORC1 activity. mTORC1 activity is 
frequently elevated in CSC including pancreatic CSCs 
[223,224,324].  
 
MET may induce S phase arrest in certain pancreatic 
cancer cell lines [324]. MET may target pancreatic CSC 
more than non-CSCs. MET has been shown to increase 
ROS in the CSC population which resulted in reduced 
mitochondrial transmembrane potential. This resulted in 
a lethal energy crisis and was AMPK/mTORC1 
independent. While MET treatment of the CSCs 
blocked their ability to expand in vitro and induced 
apoptosis, MET treatment of the non-CSCs induced cell 
cycle arrest but they were not eliminated [325.326]. 
More recent studies have shown that MET may induce 
G1 phase arrest via suppression of miRs such as miR-
221 in pancreatic cell lines such as PANC1. This 
resulted in increased sensitivity to TRAIL through 
upregulation of death receptor 5 (DR5) [327]. MET 
treatment resulted in down-regulation of miR-221 and 
increased expression of the cell cycle inhibitor p27Kip-1. 
miR-221 is normally involved in tumor development 
and can regulate TRAIL resistance. While treatment of 
pancreatic cancer cell lines with MET or TRAIL by 
themselves did not appear to induce significant 
apoptosis as judged by the percentage of Sub-G1 
population detected by propidium iodine staining and 
flow cytometric cell cycle analysis, the combined MET 
and trail treatment increased the Sub-G1 population in 
all three pancreatic cancer cells examined which was 
due to the interaction between caspases, TRAIL and 
DR5. In these studies, the effects of MET on miR-221 
expression may be important in G1 phase arrest but not 
apoptosis. An inverse relationship between miR-221 
and MET treatment has been observed in type 2 
diabetes patients [328].  
 
Diabetes patients treated with MET may have a reduced 
risk of pancreatic and other cancers [329-331]. There 
are/have been at least sixteen clinical trials examining 
the effects of combining MET with various drugs used 
in the treatment of pancreatic cancer.   
 
Effects of metformin on liver diseases 
 
MET can also inhibit pathways critical for hepatic 
lipogenesis. Inhibition of these pathways by MET can 
suppress liver tumorigenesis [332]. There have been at 
least five clinical trials with metformin and liver cancer. 
MET can activate AMPK and SIRT1 expression and 
alleviate hepatosteatosis [333].  
 
Other plant-derived chemicals on cancer 
 
Momordica charantia is commonly known as: bitter 
melon, bitter gourd, and balsam apple. It is cultivated 
world-wide and both the plant and the fruit are 
consumed. Bitter melon has been evaluated in at least 
three clinical trials with diabetes and metabolic 
syndrome patients. It has been shown to have many 
important medical properties including: anti-bacterial, 
anti-cancer, anti-diabetic, anti-inflammatory, anti-
obesity, anti-oxidant and recently it has been postulated 
to target CSCs. The bitter melon plant contains several 
components which can have effects on suppression of 
cell growth such as: cucurbitane type triterpenoids, 
essential oils, fatty acids, flavonoids, phenolic acids, 
proteins, triterpene glycosides and saponins [334].  
  
Recent studies have determined that bitter melon 
extracts contain compounds that inhibit growth of many 
types of cancer and ameliorate resistance to common 
chemotherapeutic compounds. Bittermelon extracts can 
inhibit ovarian cancer growth via activation of AMPK 
and suppression of the mTOR/p70S6K and/or the 
AKT/ERK/FOXM1 (Forhead Box M1) signaling 
cascade [335]. Alpha-Momorcharin, a ribosome 
inactivating protein, present in bitter melon extracts 
may in part be responsible for the anti-cancer effects 
[336,337].  
 
Many diverse natural products have been examined for 
their effects on the SHH pathway. SHH signaling has 
been strongly implicated in cancer development, CSCs, 
progression and resistance. The effects of various 
natural products such as: CUR, cyclopamine (a 
teratogen isolated from the corn lily Veratrum 
californicum), EGCG, genistein (a phytoestrogen 
isoflavone present in soy and other beans), 
norcantharidin (a derivative of cantharidin obtained 
from the blister beetle (Mylabris phalerata Pallas), 
RES, zerumbone (a ginger plant from Southeast Asia) 
and even arsenic trioxide have been examined on SHH 
signaling and summarized recently [338]. EGCG has 
been evaluated in at least 2 clinical trials with various 
types of cancer patients including gastric and prostate 
cancer. There are at least 33 clinical trials with genistein 
and various cancer patients.  
 
The effects of sulforaphane (present in broccoli, brussel 
sprouts, cabbage and other cruciferous vegetables), 
quercetin (a flavonol found in many fruits, grains, 
leaves and vegetables) and catechins have been 
examined on let-7 miR induction and KRAS suppres-
sion in pancreatic cancer cells. Combining green tea 
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catechins (GTCs) with sulforaphane or quercetin was 
observed to have enhanced effects on pancreatic cancer 
cells as measured by suppression MMP-2, MMP-9 and 
ALDH1 activities, colony and spheroid formation and 
the induction of apoptosis. These treatments resulted in 
induction of the let7 miR and suppression of KRAS 
[339]. 
  
Certain African potatoes are sources of the hypoxoside 
derivative Rooperol. Rooperol was determined to 
inhibit the proliferation of OCT4-expressing human 
embryonal carcinoma NT2/D1 cells which have some 
properties of CSCs. Rooperol induced the production of 
ROS and induced cell death via altering the 
mitochondrial membrane potential. Interestingly, in 
these studies, the effects of rooperol were determined to 
be TP53-dependent and rooperol induced TP53 
activation and apoptosis. Rooperol treatment decreased 
OCT4 expression and other genes associated with 
stemness such as NANOG and SOX2 [340].  
 
Pomiferin is derived from the fruit of Maclura pomifera 
(a.k.a Osage orange). This fruit has been used by 
various cultures for medicinal purposes. Pomiferin has 
been shown to inhibit the growth, self-renewal and 
invasion of glioma neuorspheres. Pomiferin inhibited 
the expression of many genes associated with stemness 
including:  BIM1, NANOG and NESTIN [341].  
 
Extract prepared from Iberis amara (a.k.a. Bitter 
candytuft) have been shown to inhibit CRC in both in 
vitro experiments and in the HT-29 tumor xenograft 
model. Some of the anti-tumoral effects of the Iberis 
amara extract were determined to occur by the 
induction of apoptosis and ROS [342].   
 
Parthenolide is derived from the plant feverfew. The 
effects of the natural products parthenolide and 
andrographolide have been examined on MM CSCs. 
NF-kappaB is a target of both parthenolide and andro-
grapholide. Both parthenolide and andrographolide 
exhibited toxicity towards the MM-CSCs as opposed to 
the non-tumorigenic MM cells [343].  
 
Certain natural products (e.g., CUR, genistein, and 
quercetin) can serve as radiosensitizers and may be 
more effective than synthetic compounds in killing 
radioresistant CSCs after radiotherapy. miRs are 
important in the regulation of radiation resistance. 
Certain natural products may alter (induce) the 
expression of miRs that inhibit genes which are 
involved in resistance and tumor progression [344].  
 
Beta-carotene (present in carrots and other fruits and 
vegetables), CUR, EGCG, piperine (present in black 
pepper), sulforaphane, genistein all have been shown to 
target and kill CSCs. There are approximately 16, 57 
and 20 clinical trials examining the effects of beta-
carotene, curcumin or sulforaphane on cancer. These 
phytochemical exert part of their growth suppressive 
effects via inhibition of the WNT signaling pathway 
which plays key roles in CSCs [345].  
 
Effects of Omega-3 polyunsaturated fatty acids on 
cancer 
 
There are many sources of omega-3 poly unsaturated 
fatty acids (PUFA) including cold water fish and flax 
seed and flax seed oil. Fish oil is composed of two types 
of omega-3 PUFA, icosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA). Flax seed oil contains 
alpha-linolenic acid (ALA) which is present in flax 
seeds, hemp, walnuts and pumpkin seeds. The top 
eleven fish in terms of omega-3 PUFA are: mackerel, 
lake trout, herring, Bluefin tuna, salmon, canned 
sardines, Atlantic sturgeon, albacore tuna, lake 
whitefish, Anchovies and bluefish. Other fish contain 
less omega-3. PUFA. PUFAs have been shown to 
suppress the growth of certain primary tumors. Recently 
the effects of PUFAs on recurrent CRCs have been 
examined in the presence and absence of FOLFOX 
chemotherapy. The effects of the PUFA on FOLFOX-
resistant CRC CSCs were also determined. These 
studies observed that the effects of PUFA could be 
enhanced by FOLFOX chemotherapy. The combination 
was more potent in inhibiting various aspects of CRC 
CSC biology. The combination treatment resulted in 
increased apoptosis and PARP cleavage and suppressed 
PI3K/PTEN/Akt/mTORC1 signaling [346]. There are 
approximately 147 clinical trials examining the effects 




The beneficial effects of natural products/nutraceuticals 
are being examined for their effects on human 
physiology in many diverse settings, from: aging, 
cancer, cardiovascular diseases, joint inflammation and 
neurodegenerative diseases. Clearly, more attention and 
research should be devoted to research on the beneficial 
and potential detrimental effects of nutraceuticals. 
Many of the effects of natural products/nutraceuticals 
are mediated by miRs and the induction of AMPK and 
ROS or suppression of the WNT/beta-catenin, 
PI3K/Akt/mTOR and RAS/MEK/ERK signaling path-
ways. Some studies have indicated that high 
concentrations of various neutraceuticals may be 
required to elicit the desired effects. However, a good, 
well-balanced diet may prevent certain diseases from 
occurring. Development of more effective delivery 
methods and chemical modifications which result in 
more potent compounds with better PD/PK properties 
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may improve the nutraceuticals for the treatment of 
certain diseases. Furthermore, more emphasis needs to 
be dedicated to educating our youth on the benefits of 
natural products/nutraceuticals and the potential harm of 
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